



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12Q 1/68, B01J 19/00	A1	(11) International Publication Number: WO 00/77261 (43) International Publication Date: 21 December 2000 (21.12.2000)
(21) International Application Number: PCT/US00/16706 (22) International Filing Date: 16 June 2000 (16.06.2000) (30) Priority Data: 09/334,113 16 June 1999 (16.06.1999) US (60) Parent Application or Grant THE ROCKEFELLER UNIVERSITY [/]; (). KREEK, Mary, Jeanne [/]; (). LAFORGE, Karl, Steven [/]; (). SPANGLER, Rudolph [/]; (). KREEK, Mary, Jeanne [/]; (). LAFORGE, Karl, Steven [/]; (). SPANGLER, Rudolph [/]; (). YAMIN, Michael, A. ; ().	Published	
(54) Title: SUSCEPTIBILITY TO NEUROTRANSMITTER FACTOR DYSFUNCTIONS DETECTED USING PLURAL BIOLOGICAL SAMPLE ARRAYS (54) Titre: SENSIBILITE AUX DYSFONCTIONNEMENTS DES NEUROTRANSMETTEURS DETECTES AU MOYEN PLUSIEURS RESEAUX D'ECHANTILLONS BIOLOGIQUES (57) Abstract <p>The present invention relates to the high throughput analysis of polymorphisms of a family of genes associated with addiction and alcohol dependence. Included are probes prepared by a variety of techniques, a sample plate that may utilize DNA chip-type technology. The invention is adapted to identify both physiological and genetic conditions of subjects so tested, and should provide a rapid and inexpensive means for accomplishing the same.</p> (57) Abrégé <p>L'invention concerne l'analyse à haut rendement de polymorphismes d'une famille de gènes associés à la toxicomanie et à la dépendance à l'alcool. L'invention concerne également des sondes préparées au moyen de différentes techniques, une plaque d'échantillons pouvant utiliser la technique du type puce à ADN. Cette invention est conçue pour identifier les états physiologique et génétique de sujets ainsi testés et elle devrait constituer un moyen rapide et peu coûteux permettant d'identifier ces états.</p>		

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 December 2000 (21.12.2000)

PCT


(10) International Publication Number
WO 00/77261 A1

- (51) International Patent Classification⁷: C12Q 1/68, B01J 19/00
- (21) International Application Number: PCT/US00/16706
- (22) International Filing Date: 16 June 2000 (16.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/334,113 16 June 1999 (16.06.1999) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/334,113 (CIP)
Filed on 16 June 1999 (16.06.1999)
- (72) Inventors; and
(75) Inventors/Applicants (for US only): KREEK, Mary, Jeanne [US/US]; Apartment PHB3, 1175 York Avenue, New York, NY 10021 (US). LAForge, Karl, Steven [US/US]; Apartment 6W, 321 West 9th Avenue, New York, NY 10025 (US). SPANGLER, Rudolph [US/US]; Apartment 12-18, 2109 Broadway, New York, NY 10023 (US).
- (74) Agent: YAMIN, Michael, A.; Klauber & Jackson, 411 Hackensack Avenue, Hackensack, NJ 07601 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

[Continued on next page]

(54) Title: SUSCEPTIBILITY TO NEUROTRANSMITTER FACTOR DYSFUNCTIONS DETECTED USING PLURAL BIOLOGICAL SAMPLE ARRAYS

Fluorescence Intensity of Custom Gel Pad Microarray Following Hybridization to Human Mu Opioid Receptor Exon I Target RNA



(57) Abstract: The present invention relates to the high throughput analysis of polymorphisms of a family of genes associated with addiction and alcohol dependence. Included are probes prepared by a variety of techniques, a sample plate that may utilize DNA chip-type technology. The invention is adapted to identify both physiological and genetic conditions of subjects so tested, and should provide a rapid and inexpensive means for accomplishing the same.

WO 00/77261 A1

Description

5

10

15

20

25

30

35

40

45

50

55

**SUSCEPTIBILITY TO NEUROTRANSMITTER FACTOR DYSFUNCTIONS
DETECTED USING PLURAL BIOLOGICAL SAMPLE ARRAYS**

FIELD OF THE INVENTION

This invention relates to methods for concurrently performing multiple biological assays by means of gel pads or chips containing microarrays of biological material, and more particularly to the examination of particular genes associated with or affected by neurotransmitters. The invention further extends to the identification and consequent prognostication and implementation of corresponding therapy for conditions that cause genetic abnormalities or aberrations particularly those that result from excessive exposure to addictive agents and alcohol. The invention extends to the fields of chemistry, biology, medicine and diagnostics.

BACKGROUND OF THE INVENTION

New technology, called VLSIPS™, has enabled the production of chips smaller than a thumbnail that contain hundreds of thousands or more of different molecular probes. These biological chips or arrays have probes arranged in arrays, each probe assigned a specific location. Biological chips have been produced in which each location has a scale of, for example, ten microns. The chips can be used to determine whether target molecules interact with any of the probes on the chip. After exposing the array to target molecules under selected test conditions, scanning devices can examine each location in the array and determine whether a target molecule has interacted with the probe at that location.

Biological chips or arrays are useful in a variety of screening techniques for obtaining information about either the probes or the target molecules. For example, a library of peptides can be used as probes to screen for drugs. The peptides can be exposed to a receptor, and those probes that bind to the receptor can be identified.

5
1 Arrays of nucleic acid probes can be used to extract sequence information from, for
2 example, nucleic acid samples. The samples are exposed to the probes under
3 conditions that allow hybridization. The arrays are then scanned to determine to which
10 4 probes the sample molecules have hybridized. One can obtain sequence information
5 by careful probe selection and using algorithms to compare patterns of hybridization
6 and non-hybridization. This method is useful for sequencing nucleic acids, as well as
7 sequence checking. For example, the method is useful in diagnostic screening for
15 8 genetic diseases or for the presence and/or identity of a particular pathogen or a strain
9 of pathogen.

10
11 Of particular interest herein are the abnormalities or polymorphisms that develop in
20 12 genes that code for proteins the expression of which is known to be affected by
13 narcotics such as opiates, cocaine or alcohol. Drug addiction continues to be a major
14 medical and social problem. It is estimated that one million or more persons in the
25 15 United States are currently addicted to heroin, with millions more worldwide.
16 Cocaine addiction and alcohol dependence are frequent co-morbid conditions in
17 heroin addicts in addition to being major primary addictions. Many studies over the
18 past thirty years have shown that these drugs disrupt physiologic systems, and that
30 19 these disruptions may contribute to drug addiction and alcohol dependence and to
20 relapse to drug or alcohol abuse following withdrawal and abstinence. Clinical
21 observations suggest that individuals differ in their response to heroin, cocaine, and
35 22 alcohol; however, little is known about specific underlying hereditary genetic factors
23 which might influence individual susceptibility to the addictive properties of these
24 substances. Recent studies in genetic epidemiology provide evidence for heritable
25 contributions to drug addiction in general and also heroin addiction specifically. A
40 26 heritable basis for alcohol dependence has long been established. Furthermore, there
27 is evidence that both common and distinct genetic factors underlie some of the
28 susceptibility for these addictive diseases. Clearly an interaction of both
29 environmental and genetic factors play a role in the addictions.

45
30
31 It is hypothesized that polymorphism exists in genes involved in the biological
32 responses to heroin, cocaine, and alcohol, and that some of these polymorphisms will

5
1 result in variant forms of the proteins they encode. Other polymorphisms which do
2 not result in amino acid changes will be useful in association and linkage studies and
3 also in genome scans. Those polymorphisms which do result in changes in amino
10 4 acid structure should be studied for function, as it is further hypothesized that some of
5 the individual variations in responses to acute or chronic exposure to, or withdrawal
6 from, heroin, cocaine, and alcohol may be mediated, in part, by the variant forms of
7 these proteins. In addition, it is believed that other genes may be involved in the
15 8 development and persistence of addiction and in relapse, and that these genes may be
9 identified by a genome scan of affected sib pairs rigorously characterized with respect
10 to the addictive diseases and related co-morbid conditions. Thus, the genes of interest
20 11 herein would desirably be studied with the assistance of the high throughput
12 capabilities of contemporary biological array technology.

13
14 With respect to the preparation of biological arrays, devices and corresponding
25 15 methods have been developed that are capable of handling multiple samples
16 simultaneously. For example, U.S. Patent No. 5,545,531 to Rava et al. discloses a
17 device that can process 96 wells, each having probe arrays that, in turn, can define as
18 many as 1,000,000 probes. Also, U.S. Patent No. 5,858,661 to Shiloh illustrates the
30 19 full exposition of a particular gene, and includes DNA chip analysis as a means of
20 exploiting the information regarding the gene for patient analysis. To date however,
21 the particular family of genes of interest herein and the manner in which they would
35 22 be disposed on such an array and studied has not been considered or addressed, and it
23 is to the achievement of this and related objectives that the present invention is
24 directed. Naturally, the ability to conduct such studies in a thorough and rapid
25 manner is highly desirable.

40 26
27 The citation of any reference herein should not be construed as an admission that such
28 reference is available as "Prior Art" to the instant application.

45 29
30 SUMMARY OF THE INVENTION
31

5 1 The present invention provides a novel means of studying genes of interest and
2 2 relevance to a variety of neurological disorders and dysfunctions, and particularly,
3 3 those genes affected by exposure to agents of addiction and alcohol dependence.
10 4 Specifically, the invention extends to a device providing a biological array on which
5 5 there are disposed a plurality of DNA and RNA sequences corresponding to the genes
6 6 of interest. This array provides a multifunction analytical capability, as it facilitates
7 7 the study of RNA abnormalities or polymorphisms, and particularly single nucleotide
15 8 polymorphisms (SNPs), will yield quantitative information as to the physiological
9 9 and/or pathological condition of the test subject, while the analysis of the DNA of the
10 10 subject will provide information regarding subject genotype and corresponding
11 11 genetic predisposition.

20 12
13 13 More particularly, the biological arrays useful herein include those arrays prepared by
14 14 the solid phase techniques as disclosed in Rava et al. *supra.*, as well as the use of
25 15 polymeric gel affixation of multiple oligonucleotide strands to e.g. a glass plate, as
16 16 disclosed by Yershov et al. (1996) *Proc. Natl. Acad. Sci. USA* 93:4913-4918, the
17 17 disclosures of which are incorporated herein by reference in their entireties.

18 18 Advantages of such gel pad microarrays include 1) high sensitivity and discriminative
30 19 power, as interrogating a base position requires only a single base call set (two to four
20 20 oligonucleotides) rather than the use of massively parallel analysis with multiple
21 21 oligonucleotides spanning the base position; 2) ease of customization; 3) low cost and
35 22 reusability - multiple reuses per chip; 4) ease of preparation - manual rather than
23 23 robotic preparation of microchips is possible; 5) real-time kinetic analysis of target
24 24 annealing or melting thermodynamics; and 6) flexibility of approach, as
25 25 oligonucleotides, cDNA, or protein can be linked to acrylamide gel pads on
40 26 microchips and enzymatic reactions can be incorporated into microchip design. These
27 27 advantages will enable future directions in mu opioid receptor SNP identification
28 28 including 1) multiple exon targets hybridized to the same chip simultaneously using
29 29 single or multiple dye labeling; 2) other methods of chemical labeling and
45 30 fragmentation of RNA targets; 3) single-stranded DNA as target, 4) single nucleotide
31 31 extension (SNE) methods, and 5) generic hexanucleotide microchip for re-sequencing
32 32 to identify novel polymorphisms, all of which are embraced herein. Other means and

1 techniques for disposing plural biological materials on a solid surface are
2 contemplated herein and considered to be a part hereof.

3
4 The invention relates to the study of both RNA and DNA to discover and analyze the
5 significance of altered gene expression and polymorphic changes, extending to single
6 nucleotide polymorphisms (SNPs) of a large family of neurotransmitter factors. The
7 family of materials and genes intended herein, includes those genes involved with the
8 following exemplary physiological and pathological states and conditions: addiction;
9 response to pain; stress; gastrointestinal function; immune function; reproductive
10 function; and signal transduction.

11
12 Particular genes of interest include the opioid system, such as, the kappa opioid
13 receptor and preprodynorphin, the mu receptor, the delta receptor, preproenkephalin,
14 the opioid-like receptor (OLR1) and orphanin FQ/ (nociceptin), corticotrophin
15 releasing factor and the corticotrophin releasing factor receptor type I,
16 preproopiomelanocortin, and related peptide ligands; the dopaminergic system,
17 including Dopaminergic receptors D1-D5, the dopamine transporter; the serotonin
18 system, including serotonin and melatonin, their particular metabolic and synthetic
19 interrelation, and 15 serotonin receptors, and the serotonin transporter; the
20 norepinephrin receptor, and related molecules, and signal transducers, such as
21 adenylyl cyclase and DARPP-32 the activity cycle of the latter which is controlled by
22 interaction with dopamine, dopamine D1 and D2 receptors, and calcineurin. DARPP-
23 32 is thought to play a role in diseases such as schizophrenia, Parkinson's disease,
24 Tourette's syndrome, drug abuse and attention deficit disorder. In addition, the
25 present invention will lead to and thereby comprehends within its scope, methods for
26 identifying agents that can be used in such treatment.

27
28 The studies in accordance with the invention are performed using both traditional and
29 novel approaches for DNA sequencing and identification of SNPs and other
30 polymorphisms. Distribution of allele and genotype frequencies is to be defined with
31 respect to ethnicity; association of specific alleles and genotypes with opiate
32 addiction, and also with cocaine addiction and alcohol dependency, may be studied.

1 Classical case-control and sib pair association and linkage disequilibrium methods are
2 used. Measurement of RNA levels of neurotransmitter factors may also be employed
3 to gauge physiological and pathological states and conditions including but not
4 limited to addiction; response to pain; stress; gastrointestinal function; immune
5 function; reproductive function; and signal transduction.

6
7 The present invention may utilize a biological chip plate comprising a plurality of test
8 wells. Each test well defines a space for the introduction of a sample and contains a
9 biological array. The array is formed on a surface of the substrate, with the probes
10 exposed to the space. A fluid handling device manipulates the plates to perform steps
11 to carry out reactions between the target molecules in samples and the probes in a
12 plurality of test wells. The biological chip plate is then interrogated by a biological
13 chip plate reader to detect any reactions between target molecules and probes in a
14 plurality of the test wells, thereby generating results of the assay. In a further
15 embodiment of the invention, the method may also include processing the results of
16 the assay with a computer. Such analysis would be useful e.g. when sequencing a
17 gene by a method that uses an algorithm to process the results of many hybridization
18 assays to provide the nucleotide sequence of the gene.

19
20 The methods of the invention can involve the binding of tagged target molecules to
21 the probes. The tags can be, for example, fluorescent markers, chemiluminescent
22 markers, light scattering markers or radioactive markers. In certain embodiments, the
23 probes are nucleic acids, such as DNA or RNA molecules. The methods can be used
24 to detect or identify polymorphisms resulting from e.g. a pathogenic organism, or
25 from the excessive exposure to damaging agents such as opiates and alcohol, or to
26 detect a human gene variant, such as the gene for a genetic disease such as cystic
27 fibrosis, diabetes, muscular dystrophy or the predisposition to certain neurological
28 disorders.

29
30 This invention also provides systems for performing the methods of this invention. In
31 an exemplary embodiment, the systems include a biological chip plate; a fluid
32 handling device that automatically performs steps to carry out assays on samples

introduced into a plurality of the test wells; a biological chip plate reader that determines in a plurality of the test wells the results of the assay and, optionally, a computer comprising a program for processing the results. The fluid handling device and plate reader can have a heater/cooler controlled by a thermostat for controlling the temperature of the samples in the test wells and robotically controlled pipets for adding or removing fluids from the test wells at predetermined times.

In certain embodiments, the probes are attached by light-directed probe synthesis. The biological chip plates can have 96 wells arranged in 8 rows and 12 columns, such as a standard microtiter plate. The probe arrays can each have at least about 100, 1000, 100,000 or 1,000,000 addressable features (e.g., probes). A variety of probes can be used on the plates, including, for example, various polymers such as peptides or nucleic acids.

The plates can have wells in which the probe array in each test well is the same. Alternatively, when each of several samples are to be subjected to several tests, each row can have the same probe array and each column can have a different array. Alternatively, all the wells can have different arrays.

Several methods of making biological chip plates are contemplated. In a method presented herein by way of non-limiting example, a wafer and a body are provided. The wafer includes a substrate and a surface to which is attached a plurality of arrays of probes. The body has a plurality of channels. The body is attached to the surface of the wafer whereby the channels each cover an array of probes and the wafer closes one end of a plurality of the channels, thereby forming test wells defining spaces for receiving samples. In a second method, a body having a plurality of wells defining spaces is provided and biological chips are provided. The pads or chips are attached to the wells so that the probe arrays are exposed to the space. Another embodiment involves providing a wafer having a plurality of probe arrays; and applying a material resistant to the flow of a liquid sample so as to surround the probe arrays, thereby creating test wells.

It is a still further object of the invention to prepare and use a biological array that includes all of the various genes associated with neurotransmitter molecules, and particularly those associated with addiction and alcohol abuse, for the efficient and thorough study of patient tissue and genetic material. Other conditions include

1 response to pain, stress, gastrointestinal function, immune function, reproductive
2 function, and signal transduction.

3
4 These and other aspects of the present invention will be better appreciated by
5 reference to the following drawings and Detailed Description.

6
7 BRIEF DESCRIPTION OF THE DRAWINGS

8 Figure 1 A-B depicts the preparation of target RNA for human Mu opioid receptor
9 (hMOR) single nucleotide polymorphism (SNP) identification by hybridization to a
10 custom gel pad microarrays. Figure 1A shows RNA transcribed in vitro from hMOR
11 exon I DNA produced by PCR application of genomic DNA isolated from study
12 subjects. A 6% polyacrylamide gel stained with SYBR® green was used. Figure 1B
13 shows RNA transcripts fragmented in 0.1N NaOH at 65°C. A 20% polyacrylamide
14 gel stained with SYBR® green was used.

15
16 Figure 2 shows the identification of the C17T SNP of hMOR by hybridization to a
17 custom gel pad oligonucleotide microarray.

18
19 Figure 3 shows the identification of the A118G SNP of hMOR by hybridization to a
20 custom gel pad oligonucleotide microarray.

21
22 Figure 4 sets forth the experimental design for hMOR SNP identification using
23 custom gel pad microarrays.

24
25 Figure 5 shows chemical labeling of fragment target RNA with TEXAS RED
26 bromoacetamide.

27
28 Figure 6 shows the fluorescence intensity of a custom gel pad microarray following
29 hybridization to hMOR exon I target RNA.

Figure 7 depicts a fluorescence microscopic image of custom gel pad microarray following hybridization to hMOR exon I target RNA.

DETAILED DESCRIPTION OF THE INVENTION

The present invention has as among its objects, the development and use of a facile method and corresponding materials for the study of plural genes and other factors believed to be affected by addictive agents and alcohol. Particularly, the invention contemplates and covers the identification of polymorphism in DNA and/or RNA from or associated with these genes or agents, and the corresponding pathological and diagnostic and therapeutic information regarding the genes of interest. The invention also contemplates the identification of alterations in expression of a plurality of genes, and the corresponding pathological and diagnostic and therapeutic information regarding the genes of interest. The genes in object are those associated with addiction and dependencies such as alcohol dependency, as well as response to pain, stress, gastrointestinal function, immune function, reproductive function, and signal transduction.

Accordingly, the present invention proposes to study the entire family of neurotransmitter genes and particularly, those associated with addiction and dependency, by the disposition of plural DNA and/or RNA fragments or probes in multiple arrays for high throughput screening. As stated earlier and as contemplated herein, the devices that may be used include the multiple arrays known as DNA chips or the like, as set forth in U.S. Patent to Rava et al., discussed earlier and incorporated herein by reference.

Thus, to the extent that the following terms are used herein, they are intended to have the following general meanings:

Complementary: Refers to the topological compatibility or matching together of interacting surfaces of a probe molecule and its target. Thus, the target and its probe

1 can be described as complementary, and furthermore, the contact surface
2 characteristics are complementary to each other.

3
4 Probe: A probe is a surface-immobilized molecule that can be recognized by a
5 particular target. Examples of probes that can be investigated by this invention
6 include, but are not restricted to, agonists and antagonists for cell membrane
7 receptors, toxins and venoms, viral epitopes, hormones (e.g., opioid peptides, steroids,
8 etc.), hormone receptors, peptides, enzymes, enzyme substrates, cofactors, drugs,
9 lectins, sugars, oligonucleotides, nucleic acids, oligosaccharides, proteins, and
10 monoclonal antibodies. Particular probes of interest herein include DNA and RNA
11 derived from genes affected by addictive agents and alcohol, such as those listed
12 above and herein.

13
14 Target: A molecule that has an affinity for a given probe. Targets may be naturally-
15 occurring or man-made molecules. Also, they can be employed in their unaltered
16 state or as aggregates with other species. Targets may be attached, covalently or
17 noncovalently, to a binding member, either directly or via a specific binding
18 substance. Examples of targets which can be employed by this invention include, but
19 are not restricted to, antibodies, cell membrane receptors, monoclonal antibodies and
20 antisera reactive with specific antigenic determinants (such as on viruses, cells or
21 other materials), drugs, oligonucleotides, nucleic acids, peptides, cofactors, lectins,
22 sugars, polysaccharides, cells, cellular membranes, and organelles. Targets are
23 sometimes referred to in the art as anti-probes. As the term "targets" is used herein,
24 no difference in meaning is intended. A "Probe Target Pair" is formed when two
25 macromolecules have combined through molecular recognition to form a complex.

26
27 Array: A collection of probes, at least two of which are different, arranged in a
28 spatially defined and physically addressable manner.

29
30 Biological Chip: A substrate having a surface to which one or more arrays of probes is
31 attached. The substrate can be, merely by way of example, silicon or glass and can
32 have the thickness of a glass microscope slide or a glass cover slip. Substrates that are

transparent to light are useful when the method of performing an assay on the chip involves optical detection. As used herein, the term also refers to a probe array and the substrate to which it is attached that form part of a wafer.

Wafer: A substrate having a surface to which a plurality of probe arrays are attached. On a wafer, the arrays are physically separated by a distance of at least about a millimeter, so that individual chips can be made by dicing a wafer or otherwise physically separating the array into units having a probe array.

Biological Chip Plate: A device having an array of biological chips in which the probe array of each chip is separated from the probe array of other chips by a physical barrier resistant to the passage of liquids and forming an area or space, referred to as a "test well," capable of containing liquids in contact with the probe array.

The general class of genes of interest may be identified as neurological markers, and particularly, neurotransmitters. Ligand-gated ion channels represent a large, evolutionarily related group of intrinsic membrane proteins that form multisubunit complexes and transduce the binding of small agonists into transient openings of ion channels. Neurotransmitters bind to these channels externally, causing a change in their conformation, allowing ions to cross the membrane and thereby alter the membrane potential. The receptors which comprise these channels have an enzyme-like specificity for particular ligands (the neurotransmitters) and are characterized by their ion selectivities, including permeability to Na⁺, K⁺, Cl⁻, etc. Recognized neurotransmitters include acetylcholine, dopamine, serotonin, epinephrine, gamma-aminobutyrate (GABA), glutamate and glycine, each recognized by distinct receptors. The super-family of ligand-gated channels includes the nicotinic acetylcholine receptor (nAChR), the serotonin receptor, the GABA receptor, and glutamate receptors.

Neurotransmitters are synthesized in brain neurons and stored in vesicles. Upon a nerve impulse, a neurotransmitter is released into the synaptic cleft, where it interacts with various postsynaptic receptors. The actions of neurotransmitters, such as

acetylcholine and serotonin, are terminated by three major mechanisms: diffusion; metabolism; and uptake back into the synaptic cleft through the actions of membrane transporter systems. Thus, the actions of any such neurotransmitter can be theoretically modulated by: agents that stimulate or inhibit its biosynthesis; agents that block its storage; agents that stimulate or inhibit its release; agents that mimic or inhibit its actions at its various postsynaptic receptors; agents that inhibit its uptake back into the nerve terminal; and agents that affect its metabolism.

The acetylcholine receptor (AChR) is divided into two main types, muscarinic and nicotinic, based on the fact that the two poisons nicotine (from tobacco), and muscarine (from mushrooms) mimic the effect of acetylcholine on different types of receptors. The muscarinic AChR is found on smooth muscle, cardiac muscle, endocrine glands and the central nervous system (CNS). The nicotinic AChR (nAChR) is located on skeletal muscle, ganglia and the CNS, mediating synaptic transmission at the neuromuscular junction, in peripheral autonomic ganglia, and in the CNS.

Nicotinic acetylcholine receptors are glycosylated multisubunit pentamers. Six different types of subunit have been identified - alpha, beta, gamma, sigma, delta and epsilon- each of molecular weight 40-60 kDa. The pentamer is made up of different combinations of the subunits. The five subunits form a ring which spans the plasma membrane of the postsynaptic cell, creating a channel. Within each subunit type, distinct subtypes have been identified, including multiple alpha subunits ($\alpha 1$ - $\alpha 9$) and beta subunits ($\beta 2$ - $\beta 4$) with related but unique sequences (Role and Berg (1996) *Neuron* 16, 1077-1085). The binding of acetylcholine or nicotine to the alpha subunit of the receptor induces a conformational change which allows the influx of sodium and calcium into the cell. The synaptic action of acetylcholine on the receptor is terminated by enzymatic cleavage by acetylcholinesterase.

CNS therapeutic applications for the acetylcholine receptors include cholinergic approaches in the treatment of Alzheimer's disease and anticholinergic drugs in the treatment of Parkinson's disease. Nicotinic cholinergic dysfunction associated

with cognitive impairment is a leading neurochemical feature of the senile dementia of the Alzheimer type. For this reason, nicotinic acetylcholine receptors have attracted considerable interest as potential therapeutic targets in Alzheimer's disease. Nicotinic acetylcholine receptors have also been implicated as potential therapeutic targets in other memory, learning and cognitive disorders and deficits, including Lewy Body dementia and attention deficit disorder. In addition, the alpha subunit of nAChR has been recognized as playing an important role in the etiology of congenital myasthenia syndromes and stimulates T cells in patients with auto-immune mediated myasthenia gravis (Croxen, R. *et al.*, (1997) *Hum Mol Genet* 6, 767-774; Sine, S.M. *et al.*, (1995) *Neuron* 15, 229-239; Katz-Levy, Y. *et al.*, (1998) *J. Neuroimmunol* 85, 78-86).

Located primarily in peripheral and central neurons, serotonin (5-hydroxytryptamine, 5-HT) receptors appear to be involved in the depolarization of peripheral neurons, pain, and the emesis reflex. Potential use of agents acting at this site include migraine, anxiety, substance abuse, and cognitive and psychotic disorders. There are at least four populations of receptors for serotonin: 5-HT₁, 5-HT₂, 5-HT₃, and 5-HT₄. Recent cloning studies suggest the existence of 5-HT₅, 5-HT₆, and 5-HT₇ subtypes as well. In addition at least five distinct subtypes of the 5-HT₂ and three subtypes of the 5-HT₃ receptors exist. Largely due to the complexity of these multiple subtypes, the physiological function of each receptor subtype has not been fully established. With the exception of the 5-HT₃ receptor, which is a ligand-gated ion channel related to NMDA, GABA and nicotinic receptors, all of the 5-HT receptor subtypes belong to the group of G-protein linked receptors.

Serotonin is implicated in the etiology or treatment of various disorders, including anxiety, depression, obsessive-compulsive disorder, schizophrenia, stroke, obesity, pain, hypertension, vascular disorders, migraine, and nausea. 5-HT is synthesized in situ from tryptophan through the actions of the enzymes tryptophan hydroxylase and aromatic L-amino acid decarboxylase. Both dietary and endogenous 5-HT are rapidly metabolized and inactivated by monoamine oxidase and aldehyde dehydrogenase to the major metabolite, 5-hydroxyindoleacetic acid (5-HIAA). The major mechanism by which the action of serotonin is terminated is by uptake through presynaptic

5
1 membranes. After 5-HT acts on its various postsynaptic receptors, it is removed from
2 the synaptic cleft back into the nerve terminal through an uptake mechanism
3 involving a specific membrane transporter in a manner similar to that of other
10 4 biogenic amines. Agents that selectively inhibit this uptake increase the concentration
5 of 5-HT at the postsynaptic receptors and have been found to be quite useful in
6 treating various psychiatric disorders, particularly depression. Selective 5-HT
7 reuptake inhibitors (SSRIs) have been investigated as potential antidepressants with
15 8 the anticipation that these agents would possess fewer side effects, such as
9 anticholinergic actions and cardiotoxicity, and would be less likely to cause sedation
10 and weight gain.

20 11
12 Three selective 5-HT uptake inhibitors, have more recently been introduced on the
13 U.S. market, Fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil) and have
14 gained immediate acceptance, each listed among the top 200 prescription drugs.

25 15
16 In addition to treating depression, several other potential therapeutic applications for
17 SSRIs have been investigated. They include treatment of Alzheimer's disease;
18 modulation of aggressive behavior; treatment of premenstrual syndrome, diabetic
30 19 neuropathy, and chronic pain; and suppression of alcohol intake. Also significant is
20 the observation that 5-HT reduces food consumption by increasing meal-induced
21 satiety and reducing hunger, thus, there is interest in the possible use of SSRIs in the
35 22 treatment of obesity.

23
24 5-HT₃ receptors have been proposed to play a major role in the physiology of emesis.
25 These receptors are found in high concentrations peripherally in the gut and centrally
40 26 in the cortical and limbic regions and in or near the chemoreceptor trigger zone, and
27 have been implicated in the vomiting reflex induced by serotonin as a result of
28 chemotherapy. Two 5-HT₃ receptor antagonists, ondansetron (Zofran) and
45 29 granisetron (Kytril), have been marketed to treat nausea associated with radiation and
30 chemotherapy in cancer patients.
31

5
1 Several family, twin, and adoption studies provide evidence for heritable
2 contributions to drug and alcohol dependency, although little is known about specific
3 underlying hereditary factors which might influence individual susceptibility to the
10 4 addictive properties of these substances [5-9] Recent familial and twin studies have
5 reported that both common and distinct heritable factors account for the genetic
6 variance in the susceptibility to the separate addictive diseases, *i.e.* that both shared
7 and independent causative factors contribute to the development of each separate type
15 8 of substance dependence [9-12]. Moreover, in a study of 3372 male twin pairs,
9 Tsuang and colleagues [9,10] found that heroin abuse had the largest amount of
10 unique genetic variance (38%) and the least amount of shared genetic variance (16%)
20 11 of any of the other abused drugs studied (marijuana, stimulants, sedatives,
12 psychedelics).

13
14 Animal studies also provide evidence for a genetic contribution to the addictive
25 15 diseases. Different strains of rodents have been shown to have differences in their
16 responses to opioids, cocaine and alcohol in models which study self-administration,
17 reinforcement, and tolerance, each of which may have potential implications for the
18 susceptibility to develop drug addiction in humans. [e.g. 13-17].

30 19
20 Many studies over the past thirty years have shown that opioids, cocaine and alcohol
21 disrupt physiologic systems, and that these disruptions may contribute to drug
35 22 addiction and alcohol dependence and to relapse to drug or alcohol abuse following
23 withdrawal and abstinence. It is hypothesized herein that polymorphism exists in
24 genes involved in the biological responses to heroin, cocaine, and alcohol, and that
25 some of these polymorphisms will result in variant forms of the proteins they encode.
40 26 Further, some of the individual variations in responses to acute or chronic exposure
27 to, or withdrawal from, heroin, cocaine, and alcohol may be mediated, in part, by
28 variant allelic forms of these genes. Moreover, other heretofore undefined genes may
29 be involved in the development and persistence of addiction and in relapse, and that
45 30 these genes may be identified by using genomic scans of sib pairs rigorously
31 characterized with respect to the addictive diseases and related comorbid conditions.
32

From the foregoing, it can be appreciated that a broad physiological and pathological range and effect is commanded by these molecules. As noted earlier, the present invention is applicable to the synthesis and study of any of the molecules included within these classes, however, focuses its primary attention on the molecules referred to earlier and discussed in detail below.

Accordingly and as stated above, the genes in question are found among the following neurotransmitters: the opioid system, such as, the kappa opioid receptor and preprodynorphin, the mu receptor, the delta receptor, preproenkephalin, the opioid-like receptor (OLR1) and orphanin FQ/ (nociceptin), corticotrophin releasing factor and the corticotrophin releasing factor receptor type I, preproopiomelanocortin, and related peptide ligands; the dopaminergic system, including Dopaminergic receptors D1-D5, the dopamine transporter; the serotonin system, including serotonin and melatonin, their particular metabolic and synthetic interrelation, and 15 serotonin receptors, and the serotonin transporter; the norepinephrin receptor, and related molecules, and signal transducers, such as adenylyl cyclase and DARPP-32.

More particularly, the following genes will be studied with a view to the examination of particular polymorphisms, as follows:

The kappa opioid receptor gene (KOR). The coding region of the KOR gene has been shown to be dispersed in three exons of 264, 352 and 533 bp in length [18,19]. The intron sequences flanking the 3' end of exon 2 is available in GenBank (Accession # U16860). The rest of the intron sequences flanking exon 2 and exon 3 have been examined, and have provided the information necessary to design primers for PCR amplification of exons 2 and 3. The sequences flanking exon 1 may be obtained by inverse PCR. Nested primers will be used for manual and automated sequencing of exon 1, 2 and 3.

The preprodynorphin gene (ppDyn). DNA of this gene may be analyzed for polymorphisms in and around exons 1, 3 and 4 of the ppDyn gene (exon 2 contains only 5' untranslated sequence). Translation starts in exon 3 and ends in exon 4, which

1 encodes the opioid peptides. The nucleotide sequence of the exons and flanking intron
2 sequences are available in GenBank (accession ## X00175, X0177). Primers
3 completely flanking exons 1 and 3 may be used for determination of sequence in
4 those exons, and primers downstream of the exon 4 border together with primers in
5 the 3' untranslated region of exon 4 may be used for determination of sequence in
6 exon 4.

7
8 The opioid receptor-like receptor (ORL1). The primary structure of the gene has been
9 reported [21]. The coding region of the receptor is interrupted by a single short 120 bp
10 intron. The published sequences flanking the coding regions of ORL1 will be used to
11 design PCR and sequencing primers.

12
13 The orphanin FQ gene (prepronociceptin). The orphanin FQ gene is composed of 4
14 exons [22]. Translation starts in exon 2 and the biologically active heptadecapeptide is
15 encoded in exon 3. The sequences flanking exons 2 and 3 will be used for PCR and
16 sequencing primer design.

17
18 The preproenkephalin gene (ppENK). The ppENK gene and cDNA sequences have
19 been published [23,24]. The ppENK gene consists of 3 exons. The opioid peptides
20 are located in exon 3. Primers completely flanking exon 2 may be used for
21 determination of sequence in that exon, and primers downstream of the exon 3 border
22 together with primers in the 3' untranslated region of exon 3 may be used for
23 determination of sequence in exon 3.

24
25 The corticotropin releasing factor gene (CRF). The CRF gene structure has been
26 published [25]. The CRF gene consists of two exons, with all the uninterrupted
27 sequence of the CRF precursor (196 amino acid) in exon 2. A primer flanking exon 2
28 upstream of the intron/exon border may be used, and the same primer in the 3'
29 untranslated region used to generate the fragment shown in Fig. 1, lane d, for
30 determination of significant sequence from the CRF gene.

5
10
15
20
25
30
35
40
45
50
55

1 The corticotropin releasing factor receptor, type1 gene (CRF-R1). A cDNA sequence
2 encoding the 415 amino acid human CRF-R1 protein has been reported [26,27]. The
3 genomic structure is apparently not yet publicly known. However, there is an
4 apparently alternatively spliced form of the CRFR1 mRNA in which 29 amino acids
5 are inserted into the first intracellular loop. The site of the insertion indicates the
6 position of a putative intron. In order to obtain the intron sequences, we will use PCR
7 amplification of human genomic DNA with primers flanking the insert in CRF-R1.
8 Sequencing of this putative intron region will enable us to design PCR and
9 sequencing primers for the coding region of CRF-R1. To define the intron/exon
10 structure of the rest of the gene overlapping sets of primer pairs will be designed
11 which amplify short sections (~200 bp) of the coding region. Genomic DNA will be
12 amplified using these primer sets and products will be analyzed for amplicons of the
13 predicted length. If longer fragments than expected are produced, or if intron
14 sequences are present that are too long to successfully amplify, this will indicate the
15 approximate position of introns. Exact intron/exon boundaries will then be determined
16 by inverse PCR as described [171].

17
18 The preproopiomelanocortin gene (POMC). The gene and cDNA structure of POMC
19 have been reported [28-30]. The POMC gene consists of 3 exons. The coding regions
20 for the biologically active peptides, ACTH and beta-lipotropin, and their smaller
21 derivatives, alpha-melanotropin, beta-melanotropin and beta-endorphin, are located in
22 exon 3.

23
24 As stated earlier, this invention provides automated methods for concurrently
25 processing multiple biological chip assays. Currently available methods utilize each
26 biological chip assay individually. The methods of this invention allow many tests to
27 be set up and processed together. Because they allow much higher throughput of test
28 samples, these methods greatly improve the efficiency of performing assays on
29 biological chips. It should be noted that the method for determining the expression of
30 a plurality of neurotransmitter genes or the method for determining the presence of
31 polymorphisms in a plurality of neurotransmitter genes for the various purposes
32 herein are not limited to any particular methods. While the use of a multiple

biological chip is a preferred embodiment, including the use of a gel pad array, and the methods of detection using the chips herein of hybridization or single nucleotide extension are preferred methods, the invention embraces any and all methods for the determination of plural genes or gene expression products. Such preferred methods are described in Khrapko KR, Lysov YP, Khorlin A, Shick VV, Florentiev VL, Mirzabekov AD. 1989. An oligonucleotide hybridization approach to DNA sequencing. FEBS Lett 256:118-122; Khrapko KR, Lysov YP, Khorlin AA, Ivanov I, B Yershov GM, Vasilenko SL, Florentiev V, Mirzabekov AD, 1991, A method for DNA sequencing by hybridization with oligonucleotide matrix. J DNA sequencing 1: 375-388; Fodor SPA, Read JL, Pirtung MC, Stryer L, Lu AT, Solas, D, 1991, Light directed, spatially addressable parallel chemical synthesis. Science 251:776-773; Southern EM, Maskos U, Elder JK, 1992, Analyzing and comparing nucleic acid sequences by hybridization to arrays of oligonucleotides: evaluation using experimental models, Genomics 13:1008-1017; Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, Winkler J, Lockhart DJ, Morris MS, Fodor SPA. 1996. Accessing genetic information with high-density DNA arrays. Science 274:610-614; Hacia JG, Brody LC, Chee MS, Fodor SPA, Collins F. 1996. Detection of heterozygous mutations in BCRA1 using high density oligonucleotide arrays and two colour fluorescence analysis. Nature Genet 14:44-447; Yershov G, Barsky V, Belgovskiy A, Kirillov E, Kreindlin E, Ivanov I, Parinov S, Guschin D, Drobishev A, Dubiley S, Mirzabekov A. 1996. DNA Analysis and diagnostics on oligonucleotide microchips. Proc Natl Acad Sci USA 93:4913-4918; Shick VV Lebed YB, Kryukov GV. 1998. Identification of HLA DQA1 alleles by the oligonucleotide microchip method. Mol Biol 32:697-688. Translated from Molekulyarna Biologiya 32:813-822; Wang DG, Fan J-B, Siao C-J, Berno A, Young P, Sapolsky R, Ghandour G, Perkins N, Winchester E, Spencer J, Kruglyak L, Stein L, Hsie L, Topaloglou T, Hubbell E, Robinson E, Mittmann M, Morris MS, Shen N, Kilburn D, Rioux J, Nusbaum C, Rozen S, Hudson TJ, Lipschutz R, Chee M, Lander ES. 1998 Large scale identification, mapping and genotyping of single-nucleotide polymorphisms in the human genome. Science 280:1077-1082; Halushka MK, Fan J-B, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A. 1999. Patterns of single-nucleotide polymorphisms in candidate genes for blood pressure homeostasis. Nature

Genet 22:239-247; Cargill M, Altschuler D, Ireland J, Sklar P, Ardlie K, Patil N, Lane CR, Lim EP, Kalyanaraman N, Nemesh J, Ziaugra L, Friedland L, Rolfe A, Warrington J, Lipshutz R, Daley GQ, Lander ES. 1999. Characterization of single nucleotide polymorphisms in coding regions of human genes. *Nature genet* 22:231-238; Parinov S, Barsky V, Yershov G, Kirillov E, Timofeev E, Belgovskiy A, Mirzabekov A. 1996. DNA sequencing by hybridization to microchip octa- and decanucleotides extended by stacked pentanucleotides. *Nucleic Acids Res* 24:2998-3004; Guschin D, Yershov G, Zaslavsky A, Gemmell A, Shick V, Proudnikov V, Arenkov P, Mirzabekov A. 1997. Manual manufacturing of oligonucleotide, DNA and protein microchips. *Anal Biochem* 250:203-211; Drobyshv A, Mologina M. Shik V, Pobedinskaya D, Yershov G, Mirzabekov A. 1997. Sequence analysis by hybridization with oligonucleotide microchip: Identification of b-thalassemia mutations. *Gene* 188:45-52; Syvänen A-C, Aalto-Setälä K, Harju L, Kontula K, SØderlund H. 1990. A primer-guided nucleotide incorporation assay in the genotyping of apolipoprotein E. *Genomics* 8:684-692; Pastinen T, Kurg A, Metspalu A, Peltonen L, Syvänen A-C. 1997. Minisequencing: A specific tool for DNA analysis and diagnostics on oligonucleotide arrays. *Genome res* 7:606-614; Pastinen T, Perola M, Niini P, Terwilliger J, Salomaa V, Vartiainen E, Peltonen L, Syvänen A-C. 1998. Array-based multiplex analysis of candidate gene reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. *Hum Mol Genet* 7:1453-1462; Dubiley S, Kirillov E, Mirzabekov A. 1999. Polymorphism analysis and gene detection by minisequencing on an array of gel-immobilized primers. *Nucleic Acids Res* 27:e19; and Syvänen A-C. 1999. From gels to chips: "Minisequencing" primer extension analysis of point mutations and single nucleotide polymorphisms. *Hum Mutat* 13:1-10. However, as noted above, it is not limited to any particular method. The following discussion pertains to one such embodiment, the use of the multiple biological chip array.

In the methods of this invention, a biological chip plate is provided having a plurality of test wells. Each test well includes a biological chip. Test samples, which may contain target molecules, are introduced into the test wells. A fluid handling device exposes the test wells to a chosen set of reaction conditions by, for example, adding or

5
1 removing fluid from the wells, maintaining the liquid in the wells at predetermined
2 temperatures, and agitating the wells as required, thereby performing the test. Then, a
3 biological chip reader interrogates the probe arrays in the test wells, thereby obtaining
10 4 the results of the tests. A computer having an appropriate program can further
5 analyze the results from the tests.
6

7 Individual chips may have attached to them a plurality of probes, the probes in turn
15 8 prepared by the following exemplary protocol. Thus, sequences flanking coding
9 regions of human receptor and prepropeptide genes may be used to design PCR
10 primers for use in the amplification. Optimal forward and reverse primers are selected
20 11 with the aid of the primer analysis software, Oligo 4.1 (National Biosciences, MN).
12 We will use step-down PCR [170], which will add specificity during those cycles
13 above the melting temperature (T_m) of an oligonucleotide duplex, as well as enhanced
14 efficiency during those cycles below the T_m , to simultaneously increase both product
25 15 yield and homogeneity. Preliminary optimization of annealing temperature and PCR
16 cycling is performed using the Eppendorf Mastercycler Gradient. PCR amplification
17 is carried out in 50 to 100 μ l reactions with 200 ng genomic DNA, 20 pmol of each
30 18 primer, 200 mM of each dNTP, 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM
19 $MgCl_2$, and 2.5 U Taq polymerase. Samples are cycled 30 sec at 94°C, with annealing
20 for 45 sec at a variable (step-down) or a fixed temperature, then elongation for 30 sec
21 at 72°C, followed by a final elongation period of 5 min at 72°C. PCR products are
35 22 analyzed by electrophoresis in agarose gels and visualized by ethidium bromide
23 staining. Single band PCR products are purified by QIAquick PCR purification Kit
24 (Qiagen); if there is more than one fragment, the correct fragment is isolated from the
25 gel and purified by QIAquick Gel Extraction Kit (Qiagen).
40 26

27 Further, an exemplary system includes a biological chip plate reader, a fluid handling
28 device, a biological chip plate and, optionally, a computer. In operation, samples are
45 29 placed in wells on the chip plate with fluid handling device. The plate optionally can
30 be moved with a stage translation device. The reader is used to identify where targets
31 in the wells have bound to complementary probes. The system operates under control
32 of computer which may optionally interpret the results of the assay.

5
1 A. Biological Chip Plate Reader
2

3 In assays performed on biological chips, detectably labeled target molecules bind to
4 probe molecules. Reading the results of an assay involves detecting a signal produced
10 5 by the detectable label. Reading assays on a biological chip plate requires a biological
6 chip reader. Accordingly, locations at which target(s) bind with complementary
7 probes can be identified by detecting the location of the label. Through knowledge of
15 8 the characteristics/sequence of the probe versus location, characteristics of the target
9 can be determined. The nature of the biological chip reader depends upon the
10 particular type of label attached to the target molecules.

20 11
12 The interaction between targets and probes can be characterized in terms of kinetics
13 and thermodynamics. As such, it may be necessary to interrogate the array while in
14 contact with a solution of labeled targets. In such systems, the detection system must
25 15 be extremely selective, with the capacity to discriminate between surface-bound and
16 solution-born targets. Also, in order to perform a quantitative analysis, the high-
17 density of the probe sequences requires the system to have the capacity to distinguish
18 between each feature site. The system also should have sensitivity to low signal and a
30 19 large dynamic range.

20 21
22 In one embodiment, the chip plate reader includes a confocal detection device having
35 23 a monochromatic or polychromatic light source, a focusing system for directing an
24 excitation light from the light source to the substrate, a temperature controller for
25 controlling the substrate temperature during a reaction, and a detector for detecting
40 26 fluorescence emitted by the targets in response to the excitation light. The detector for
27 detecting the fluorescent emissions from the substrate, in some embodiments, includes
28 a photomultiplier tube. The location to which light is directed may be controlled by,
29 for example, an x-y-z translation table. Translation of the x-y-z table, temperature
45 30 control, and data collection are managed and recorded by an appropriately
31 programmed digital computer.

5
10
15
20
25
30
35
40
45
50
55

1 FIG. 2 of U.S. Patent No. 5,545,531, illustrates a reader according to one specific
2 embodiment. The chip plate reader comprises a body 200 for immobilizing the
3 biological chip plate. Excitation radiation, from an excitation source 210 having a first
4 wavelength, passes through excitation optics 220 from below the array. The light
5 passes through the chip plate since it is transparent to at least this wavelength of light.
6 The excitation radiation excites a region of a probe array on the biological chip plate
7 230. In response, labeled material on the sample emits radiation which has a
8 wavelength that is different from the excitation wavelength. Collection optics 240,
9 also below the array, then collect the emission from the sample and image it onto a
10 detector 250, which can house a CCD array, as described below. The detector
11 generates a signal proportional to the amount of radiation sensed thereon. The signals
12 can be assembled to represent an image associated with the plurality of regions from
13 which the emission originated.

14
15 According to one embodiment, a multi-axis translation stage 260 moves the biological
16 chip plate to position different wells to be scanned, and to allow different probe
17 portions of a probe array to be interrogated. As a result, a 2-dimensional image of the
18 probe arrays in each well is obtained.

19
20 The biological chip reader can include auto-focusing feature to maintain the sample in
21 the focal plane of the excitation light throughout the scanning process. Further, a
22 temperature controller may be employed to maintain the sample at a specific
23 temperature while it is being scanned. The multi-axis translation stage, temperature
24 controller, auto-focusing feature, and electronics associated with imaging and data
25 collection are managed by an appropriately programmed digital computer 270.

26
27 In one embodiment, a beam is focused onto a spot of about 2 μm in diameter on the
28 surface of the plate using, for example, the objective lens of a microscope or other
29 optical means to control beam diameter.

30
31 In another embodiment, fluorescent probes are employed in combination with CCD
32 imaging systems. In many commercially available microplate readers, typically the

5
1 light source is placed above a well, and a photodiode detector is below the well. In the
2 present invention, the light source can be replaced with a higher power lamp or laser.
3 In one embodiment, the standard absorption geometry is used, but the photodiode
10 4 detector is replaced with a CCD camera and imaging optics to allow rapid imaging of
5 the well. A series of Raman holographic or notch filters can be used in the optical path
6 to eliminate the excitation light while allowing the emission to pass to the detector. In
7 a variation of this method, a fiber optic imaging bundle is utilized to bring the light to
15 8 the CCD detector. In another embodiment, the laser is placed below the biological
9 chip plate and light directed through the transparent wafer or base that forms the
10 bottom of the biological chip plate. In another embodiment, the CCD array is built
20 11 into the wafer of the biological chip plate.
12

13 In another embodiment, the detection device comprises a line scanner, as described in
14 U.S. patent application Ser. No. 08/301,051, filed Sep. 2, 1994, incorporated herein
25 15 by reference. Excitation optics focuses excitation light to a line at a sample,
16 simultaneously scanning or imaging a strip of the sample. Surface bound labeled
17 targets from the sample fluoresce in response to the light. Collection optics image the
18 emission onto a linear array of light detectors. By employing confocal techniques,
30 19 substantially only emission from the light's focal plane is imaged. Once a strip has
20 been scanned, the data representing the 1-dimensional image are stored in the memory
21 of a computer. According to one embodiment, a multi-axis translation stage moves the
35 22 device at a constant velocity to continuously integrate and process data. Alternatively,
23 galvometric scanners or rotating polyhedral mirrors may be employed to scan the
24 excitation light across the sample. As a result, a 2-dimensional image of the sample is
25 obtained.
40 26

27 In another embodiment, collection optics direct the emission to a spectrograph which
28 images an emission spectrum onto a 2-dimensional array of light detectors. By using a
45 29 spectrograph, a full spectrally resolved image of the sample is obtained.
30

31 The read time for a full microtiter plate will depend on the photophysics of the
32 fluorophore (i.e. fluorescence quantum yield and photodestruction yield) as well as
50

5
1 the sensitivity of the detector. For fluorescein, sufficient signal-to-noise to read a chip
2 image with a CCD detector can be obtained in about 30 seconds using 3 mW/cm² and
3 488 nm excitation from an Ar ion laser or lamp. By increasing the laser power, and
10 4 switching to dyes such as CY3 or CY5 which have lower photodestruction yields and
5 whose emission more closely matches the sensitivity maximum of the CCD detector,
6 one easily is able to read each well in less than 5 seconds. Thus, an entire plate could
7 be examined quantitatively in less than 10 minutes, even if the whole plate has over
15 8 4.5 million probes.

9
10 A computer can transform the data into another format for presentation. Data analysis
11 can include the steps of determining, e.g., fluorescent intensity as a function of
20 12 substrate position from the data collected, removing "outliers" (data deviating from a
13 predetermined statistical distribution), and calculating the relative binding affinity of
14 the targets from the remaining data. The resulting data can be displayed as an image
25 15 with color in each region varying according to the light emission or binding affinity
16 between targets and probes therein.

17
18 One application of this system when coupled with the CCD imaging system that
30 19 speeds performance of the tests is to obtain results of the assay by examining the on-
20 or off-rates of the hybridization. In one embodiment of this method, the amount of
21 binding at each address is determined at several time points after the probes are
35 22 contacted with the sample. The amount of total hybridization can be determined as a
23 function of the kinetics of binding based on the amount of binding at each time point.
24 Thus, it is not necessary to wait for equilibrium to be reached. The dependence of the
25 hybridization rate for different oligonucleotides on temperature, sample agitation,
40 26 washing conditions (e.g. pH, solvent characteristics, temperature) can easily be
27 determined in order to maximize the conditions for rate and signal-to-noise.
28 Alternative methods are described in Fodor et al., U.S. Pat. No. 5,324,633,
45 29 incorporated herein by reference.

30
31 Assays on biological arrays generally include contacting a probe array with a sample
32 under the selected reaction conditions, optionally washing the well to remove

5
1 unreacted molecules, and analyzing the biological array for evidence of reaction
2 between target molecules the probes. These steps involve handling fluids. The
3 methods of this invention automate these steps so as to allow multiple assays to be
10 4 performed concurrently. Accordingly, this invention employs automated fluid
5 handling systems for concurrently performing the assay steps in each of the test wells.
6 Fluid handling allows uniform treatment of samples in the wells. Microtiter robotic
7 and fluid-handling devices are available commercially, for example, from Tecan AG.

15 8
9 The plate is introduced into a holder in the fluid-handling device. This robotic device
10 is programmed to set appropriate reaction conditions, such as temperature, add
20 11 samples to the test wells, incubate the test samples for an appropriate time, remove
12 unreacted samples, wash the wells, add substrates as appropriate and perform
13 detection assays. The particulars of the reaction conditions depends upon the purpose
14 of the assay. For example, in a sequencing assay involving DNA hybridization,
25 15 standard hybridization conditions are chosen. However, the assay may involve testing
16 whether a sample contains target molecules that react to a probe under a specified set
17 of reaction conditions. In this case, the reaction conditions are chosen accordingly.

30 18
19 FIG. 3 of Rava et al. depicts an example of a biological chip plate that may be used in
20 the methods of this invention based on the standard 96-well microtiter plate in which
21 the chips are located at the bottom of the wells. Biological chip plates include a
35 22 plurality of test wells 310, each test well defining an area or space for the introduction
23 of a sample, and each test well comprising a biological chip 320, i.e., a substrate and a
24 surface to which an array of probes is attached, the probes being exposed to the space.
25 FIG. 7 shows a top-down view of a well of a biological chip plate of this invention
40 26 containing a biological chip on the bottom surface of the well.

27
28 This invention contemplates a number of embodiments of the biological chip plate. In
29 a preferred embodiment, depicted in FIG. 4, the biological chip plate includes two
45 30 parts. One part is a wafer 410 that includes a plurality of biological arrays 420. The
31 other part is the body of the plate 430 that contains channels 440 that form the walls
32 of the well, but that are open at the bottom. The body is attached to the surface of the

1 wafer so as to close one end of the channels, thereby creating wells. The walls of the
2 channels are placed on the wafer so that each surrounds and encloses the probe array
3 of a biological array. FIG. 5 depicts a cross-section of this embodiment, showing the
4 wafer 510 having a substrate 520 (preferably transparent to light) and a surface 530 to
5 which is attached an array of probes 540. A channel wall 550 covers a probe array on
6 the wafer, thereby creating well spaces 560. The wafer can be attached to the body by
7 any attachment means known in the art, for example, gluing (e.g., by ultraviolet-
8 curing epoxy or various sticking tapes), acoustic welding, sealing such as vacuum or
9 suction sealing, or even by relying on the weight of the body on the wafer to resist the
10 flow of fluids between test wells.

11
12 In another preferred embodiment, depicted in cross section in FIG. 6, the plates
13 include a body 610 having preformed wells 620, usually flat-bottomed. Individual
14 biological chips 630 are attached to the bottom of the wells so that the surface
15 containing the array of probes 640 is exposed to the well space where the sample is to
16 be placed.

17
18 In another embodiment, the biological chip plate has a wafer having a plurality of
19 probe arrays and a material resistant to the flow of a liquid sample that surrounds each
20 probe array. For example, in an embodiment useful for testing aqueous-based
21 samples, the wafer can be scored with waxes, tapes or other hydrophobic materials in
22 the spaces between the arrays, forming cells that act as test wells. The cells thus
23 contain liquid applied to an array by resisting spillage over the barrier and into
24 another cell. If the sample contains a non-aqueous solvent, such as an alcohol, the
25 material is selected to be resistant to corrosion by the solvent.

26
27 The microplates of this invention have a plurality of test wells that can be arrayed in a
28 variety of ways. In one embodiment, the plates have the general size and shape of
29 standard-sized microtiter plates having 96 wells arranged in an 8×12 format. One
30 advantage of this format is that instrumentation already exists for handling and
31 reading assays on microtiter plates. Therefore, using such plates in biological chip

assays does not involve extensive re-engineering of commercially available fluid handling devices. However, the plates can have other formats as well.

The material from which the body of the biological chip plate is made depends upon the use to which it is to be put. In particular, this invention contemplates a variety of polymers already used for microtiter plates including, for example, (poly)tetrafluoroethylene, (poly)vinylidenedifluoride, polypropylene, polystyrene, polycarbonate, or combinations thereof. When the assay is to be performed by sending an excitation beam through the bottom of the plate collecting data through the bottom of the plate, the body of the plate and the substrate of the chip should be transparent to the wavelengths of light being used.

The arrangement of probe arrays in the wells of a microplate depends on the particular application contemplated. For example, for diagnostic uses involving performing the same test on many samples, every well can have the same array of probes. If several different tests are to be performed on each sample, each row of the plate can have the same array of probes and each column can contain a different array. Samples from a single patient are introduced into the wells of a particular column. Samples from a different patient are introduced into the wells of a different column. In still another embodiment, multiple patient samples are introduced into a single well. If a well indicates a "positive" result for a particular characteristic, the samples from each patient are then rerun, each in a different well, to determine which patient sample gave a positive result.

The biological chip plates used in the methods of this invention include biological chips. The array of probe sequences can be fabricated on the biological chip according to the pioneering techniques disclosed in U.S. Pat. No. 5,143,854, PCT WO 92/10092, PCT WO 90/15070, or U.S. application Ser. Nos. 08/249,188, 07/624,120, and 08/082,937, incorporated herein by reference for all purposes. The combination of photolithographic and fabrication techniques may, for example, enable each probe sequence ("feature") to occupy a very small area ("site" or "location") on the support. In some embodiments, this feature site may be as small as a few microns or even a

5
1 single molecule. For example, a probe array of 0.25 mm^2 (about the size that would fit
2 in a well of a typical 96-well microtiter plate) could have at least 10, 100, 1000, 10^4 ,
3 10^5 or 10^6 features. In an alternative embodiment, such synthesis is performed
10 4 according to the mechanical techniques disclosed in U.S. Pat. No. 5,384,261,
5 incorporated herein by reference.
6

7 Referring to FIG. 8, in general, linker molecules, O—X, are provided on a substrate.
15 8 The substrate is preferably flat but may take on a variety of alternative surface
9 configurations. For example, the substrate may contain raised or depressed regions on
10 which the probes are located. The substrate and its surface preferably form a rigid
20 11 support on which the sample can be formed. The substrate and its surface are also
12 chosen to provide appropriate light-absorbing characteristics. For instance, the
13 substrate may be functionalized glass, Si, Ge, GaAs, GaP, SiO_2 , SiN_4 , modified
14 silicon, or any one of a wide variety of gels or polymers such as
25 15 (poly)tetrafluoroethylene, (Poly)vinylidenedifluoride, polystyrene, polycarbonate,
16 polypropylene, or combinations thereof. Other substrate materials will be readily
17 apparent to those of skill in the art upon review of this disclosure. In a preferred
18 embodiment the substrate is flat glass or silica.
30 19

20 Surfaces on the solid substrate usually, though not always, are composed of the same
21 material as the substrate. Thus, the surface may be composed of any of a wide variety
35 22 of materials, for example, polymers, plastics, resins, polysaccharides, silica or silica-
23 based materials, carbon, metals, inorganic glasses, membranes, or any of the above-
24 listed substrate materials. In one embodiment, the surface will be optically transparent
25 and will have surface Si—OH functionalities, such as those found on silica surfaces.
40 26

27 A terminal end of the linker molecules is provided with a reactive functional group
28 protected with a photoremovable protective group, O—X. Using lithographic
29 methods, the photoremovable protective group is exposed to light, hv, through a
45 30 mask, M_1 , that exposes a selected portion of the surface, and removed from the linker
31 molecules in first selected regions. The substrate is then washed or otherwise
32 contacted with a first monomer that reacts with exposed functional groups on the

linker molecules (T—X). In the case of nucleic acids, the monomer can be a phosphoramidite activated nucleoside protected at the 5'-hydroxyl with a photolabile protecting group.

A second set of selected regions, thereafter, exposed to light through a mask, M₂, and photoremovable protective group on the linker molecule/protected amino acid or nucleotide is removed at the second set of regions. The substrate is then contacted with a second monomer containing a photoremovable protective group for reaction with exposed functional groups. This process is repeated to selectively apply monomers until polymers of a desired length and desired chemical sequence are obtained. Photolabile groups are then optionally removed and the sequence is, thereafter, optionally capped. Side chain protective groups, if present, are also removed.

The general process of synthesizing probes by removing protective groups by exposure to light, coupling monomer units to the exposed active sites, and capping unreacted sites is referred to herein as "light-directed probe synthesis." If the probe is an oligonucleotide, the process is referred to as "light-directed oligonucleotide synthesis" and so forth.

The probes can be made of any molecules whose synthesis involves sequential addition of units. This includes polymers composed of a series of attached units and molecules bearing a common skeleton to which various functional groups are added. Polymers useful as probes in this invention include, for example, both linear and cyclic polymers of nucleic acids, polysaccharides, phospholipids, and peptides having either α -, β -, or ω -amino acids, heteropolymers in which a known drug is covalently bound to any of the above, polyurethanes, polyesters, polycarbonates, polyureas, polyamides, polyethyleneimines, polyarylene sulfides, polysiloxanes, polyimides, polyacetates, or other polymers which will be apparent upon review of this disclosure. Molecules bearing a common skeleton include benzodiazepines and other small molecules, such as described in U.S. Pat. No. 5,288,514, incorporated herein by reference.

5
1 Preferably, probes are arrayed on a chip in addressable rows and columns in which the
2 dimensions of the chip conform to the dimension of the plate test well. Technologies
3 already have been developed to read information from such arrays. The amount of
10 4 information that can be stored on each plate of chips depends on the lithographic
5 density which is used to synthesize the wafer. For example, if each feature size is
6 about 100 microns on a side, each array can have about 10,000 probe addresses in a 1
7 cm² area. A plate having 96 wells would contain about 192,000 probes. However, if
15 8 the arrays have a feature size of 20 microns on a side, each array can have close to
9 50,000 probes and the plate would have over 4,800,000 probes.

10
11 The selection of probes and their organization in an array depends upon the use to
20 12 which the biological chip will be put. In one embodiment, the chips are used to
13 sequence or re-sequence nucleic acid molecules, or compare their sequence to a
14 referent molecule. Re-sequencing nucleic acid molecules involves determining
25 15 whether a particular molecule has any deviations from the sequence of reference
16 molecule. For example, in one embodiment, the plates are used to identify in a
17 particular type of HIV in a set of patient samples. Tiling strategies for sequence
18 checking of nucleic acids are described in U.S. patent application Ser. No. 08/284,064
30 19 (PCT/US94/12305), incorporated herein by reference.

20
21 In typical diagnostic applications, a solution containing one or more targets to be
35 22 identified (i.e., samples from patients) contacts the probe array. The targets will bind
23 or hybridize with complementary probe sequences. Accordingly, the probes will be
24 selected to have sequences directed to (i.e., having at least some complementarity
25 with) the target sequences to be detected, e.g., human or pathogen sequences.
40 26 Generally, the targets are tagged with a detectable label. The detectable label can be,
27 for example, a luminescent label, a light scattering label or a radioactive label.
28 Accordingly, locations at which targets hybridize with complimentary probes can be
29 identified by locating the markers. Based on the locations where hybridization occurs,
45 30 information regarding the target sequences can be extracted. The existence of a
31 mutation may be determined by comparing the target sequence with the wild type.
32

5 1 In a preferred embodiment, the detectable label is a luminescent label. Useful
2 luminescent labels include fluorescent labels, chemi-luminescent labels, bio-
3 luminescent labels, and colorimetric labels, among others. Most preferably, the label
4 is a fluorescent label such as fluorescein, rhodamine, cyanine and so forth.

10 5 Fluorescent labels include, inter alia, the commercially available fluorescein
6 phosphoramidites such as Fluoreprime (Pharmacia), Fluoredate (Millipore) and FAM
7 (ABI). For example, the entire surface of the substrate is exposed to the activated
15 8 fluorescent phosphoramidite, which reacts with all of the deprotected 5'-hydroxyl
9 groups. Then the entire substrate is exposed to an alkaline solution (eg., 50%
10 ethylenediamine in ethanol for 1-2 hours at room temperature). This is necessary to
11 remove the protecting groups from the fluorescein tag.

20 12
13 To avoid self-quenching interactions between fluorophores on the surface of a
14 biological chip, the fluorescent tag monomer should be diluted with a non-fluorescent
25 15 analog of equivalent reactivity. For example, in the case of the fluorescein
16 phosphoramidites noted above, a 1:20 dilution of the reagent with a non-fluorescent
17 phosphoramidite such as the standard 5'-DMT-nucleoside phosphoramidites, has been
18 found to be suitable. Correction for background non-specific binding of the
30 19 fluorescent reagent and other such effects can be determined by routine testing.

20 20
21 Useful light scattering labels include large colloids, and especially the metal colloids
22 such as those from gold, selenium and titanium oxide.

35 23
24 Radioactive labels include, for example, ^{32}P . This label can be detected by a
25 phosphoimager. Detection of course, depends on the resolution of the imager.
40 26 Phosphoimagers are available having resolution of 50 microns. Accordingly, this
27 label is currently useful with chips having features of that size.

28
29 The clinical setting requires performing the same test on many patient samples. The
45 30 automated methods of this invention lend themselves to these uses when the test is
31 one appropriately performed on a biological chip. For example, a DNA array can
32 determine the particular strain of a pathogenic organism based on characteristic DNA

1 sequences of the strain. The advanced techniques based on these assays now can be
2 introduced into the clinic. Fluid samples from several patients are introduced into the
3 test wells of a biological chip plate and the assays are performed concurrently.

4
5 In some embodiments, it may be desirable to perform multiple tests on multiple
6 patient samples concurrently. According to such embodiments, rows (or columns) of
7 the microtiter plate will contain probe arrays for diagnosis of a particular disease or
8 trait. For example, one row might contain probe arrays designed for a particular
9 cancer, while other rows contain probe arrays for another cancer. Patient samples are
10 then introduced into respective columns (or rows) of the microtiter plate. For
11 example, one column may be used to introduce samples from patient "one," another
12 column for patient "two" etc. Accordingly, multiple diagnostic tests may be
13 performed on multiple patients in parallel. In still further embodiments, multiple
14 patient samples are introduced into a single well. In a particular well indicator the
15 presence of a genetic disease or other characteristic, each patient sample is then
16 individually processed to identify which patient exhibits that disease or trait. For
17 relatively rarely occurring characteristics, further order-of-magnitude efficiency may
18 be obtained according to this embodiment.

19
20 In the present invention, an advantage resides in the utilization of a particular protocol
21 and the preparation of what are known as gel pads, as an example of the chip
22 constructions discussed at length above. The gel pad technique has been specifically
23 developed for the ability demonstrated herein, to prepare and analyze multiple genes
24 and corresponding multiple polymorphisms with greater speed, accuracy and
25 economy. Among the advantages of the gel pad constructions of the invention, is
26 their reusability. Further detail regarding preparations and examples of analyses
27 performed with the gel pad arrays of the invention, follow below. It should be noted
28 that the present invention is not limited to any particular method or format for
29 carrying out the detection of polymorphisms in a plurality of genes; the examples of
30 microarrays including gel pads are merely illustrative of large number of methods for
31 achieving this purpose, all of which are embraced herein.
32

5
1 In accordance with the invention, two different technologies may be employed by way
2 of example. The first is a custom made micro-array gel chip for detection of
3 polymorphisms have been and will be identified in the mu opioid receptor [57]. This
10 4 chip validates the technology using DNA for which the sequence has already been
5 determined by conventional manual or automated sequencing methods. These DNA
6 samples are from persons both heterozygotic and homozygotic for the SNPs under
7 study. Following validation of the technology, this chip may be used for high-
15 8 throughput identification of these polymorphisms as well as other polymorphisms of
9 different genes which have been or will be identified in additional uncharacterized
10 samples. The second example of a type of chip to be used will be an established
20 11 genetic micro-array gel chip for searching for novel polymorphisms in selected exon
12 regions of genes of known sequence.

13
14 Manual manufacturing of chips containing custom microarrays of oligonucleotides for
25 15 validation of known SNPs. Chips may be custom prepared following established
16 procedures [173] with recent improvements. For example, the micromatrix may be
17 manually prepared on a 75 x 25 x 1 mm glass microscope slide (Corning Micro
18 Slides) pretreated with Bind-Silane (LKB). A polymerization chamber consisting of a
30 19 quartz mask (100 x 100 x 1.5 mm) pretreated with Repel-Silane (LKB), followed by
20 treatment with 0.01 % Tween 20, is clamped onto the slide separated by two 20 µm
21 thick Teflon spacers. Polyacrylamide gel solution may consist of 4 % acrylamide
35 22 with an acrylamide:bisacrylamide ratio of 19:1. The gel solution may contain 40%
23 glycerol, a nonfluorescing catalyst, 0.012% TEMED, and 0.1 M sodium phosphate
24 buffer, pH 7.0. The gel solution is loaded into the chamber by capillary action and the
25 assembly exposed to 320 nm UV light from a distance of 1 in for 30 min. Because
40 26 the internal side of the quartz mask has an opaque photolithographed chromium film,
27 the polyacrylamide gel will polymerize only in the transparent regions, forming
28 "pads" of acrylamide gel of selected sizes - either 60 x 60 µm or 100 x 100 µm pads
29 of 20 µm thickness. The smaller pads may be separated by 120 µm and the larger pads
45 30 by 200 µm. Following polymerization, the micromatrix on the slide is washed with
31 water to remove nonpolymerized acrylamide, dried, and kept at room temperature

until ready for application of oligonucleotides. Alternative protocols for fragmentation and labeling are set forth below.

Alternate Preparation No. 1: Ferrous/EDTA-generated radicals. Each reaction contains 10 microgram of 300 base T7-generated cRNA from human sample # 1. This is the same material used for labelling by alkali lysis followed by kinasing and Texas Red bromoacetamide. In a final volume of 100 microliters: 33 microliters H₂O, 5 microliters of 2 micrograms/microliter cRNA (final 0.1 micrograms / microliter; ca. 100 picomoles); 35 microliters of 10 M urea (final 3.5 M); 10 microliters of 0.2 M sodium phosphate, pH 7 (final 0.02 M); 1 microliters of 0.1 M Fe/EDTA 2: 1 complex (final 0.001 M); and 1 microliters of 0.1 M Lissamine rhodamine B ethylenediamine (Molecular Probes, Eugene OR). The mixture was heated at 95 C for 3 min. Five microliters 0.68 % H₂O₂ was added (final = 0.01 M), and heated at 95 C for 10 min. Ten microliters of thiourea was added to stop the reaction. After incubating at room temperature for 1 min, 10 microliters 0.2 M NaCNBH₄ was added for Schiff base reduction. After incubation at room temperature for 10 min, 300 microliters of 96% ethanol / 0.4 M sodium acetate, pH 5.2 was added. The mixture was chilled at -20 C for 2 hours, spun at 10,000 x g for 10 minutes, washed with 80% ethanol, and dried. Thirty microliters 0.001 M EDTA, pH 8, was added. The size was confirmed by 15% acrylamide gel analysis: 5-10 hits per molecule. Two microliters was added to the hybridization mix for application to the array matrix.

Alternate Preparation No. 2: Phenanthroline/copper generation of radicals for fragmentation. Each reaction contains 10 microgram of 300 base T7-generated cRNA from human sample # 1. This is the same material used for labelling by alkali lysis followed by kinasing and Texas Red bromoacetamide. In a final volume of 100 microliters: 17 microliters H₂O, 5 microliters of 2 micrograms/microliter cRNA (final 0.1 micrograms/microliters; ca.100 picomoles); 35 microliters of 10 M urea (final 3.5 M); 10 microliters of 0.2 M sodium phosphate, pH 7 (final 0.02 M); 15 microliters of 0.3 M O-phenanthroline (final 0.045 M); 10 microliters of 0.045 M cupric sulfate

(final 0.0045 M); 5 microliters of 0.4 M NaCNBH₄ (final 0.02 M); and 1 microliter of 0.1 M Lissamine rhodamine B ethylenediamine (Molecular Probes, Eugene OR).

The mixture was heated at 95 C for 3 min. Two microliters 3.4 % H₂O₂ was added (final = 0.02 M), and heated at 95 C for 10 min. Six microliters of 0.5 M EDTA was added to stop the reaction. After incubating at room temperature for 10 min, 300 microliters of 96% ethanol / 0.4 M sodium acetate, pH 5.2 was added. The mixture was chilled at -20 C for 2 hours, spun at 10,000 x g for 10 minutes, washed with 80% ethanol, and dried. Thirty microliters 0.001 M EDTA, pH 8, was added. The size was confirmed by 15% acrylamide gel analysis: 3-6 hits per molecule. Two microliters was added to the hybridization mix for application to the array matrix

Just prior to application of oligonucleotides, the polyacrylamide gel matrix is activated by treatment with 2 mL of 100% hydrazine hydrate (Sigma) at room temperature for 40 min. The micromatrix is then washed in 2 mL of water, placed in 2 mL of 1% acetic acid for 10 min, washed with water, placed in 1 M NaCl for 20 min, washed with water, dried and treated with Repel-Silane for 1 min to prevent accidental diffusion of solutions between the gel pads. The slides will then be washed in ethanol followed by water and used for the preparation of custom microchips. Solutions containing 50 µl of 100 micromolar oligonucleotides with 3-methyluridine at the 3' end will be oxidized by addition of 5 µl of 50 mM sodium periodate in water for 10 min at room temperature. Oligonucleotides will be precipitated from solution with 10 volumes of 2% LiClO₄ in acetone and washed with acetone. The dried pellet will be resuspended in distilled water and stored at 4°C for short term storage or at -20°C for up to one month.

Oligonucleotides are applied to the pads in a solution of approximately 1 nl by .3 means of a simple manual pin device whose temperature is kept close to the dew point by means of a Peltier thermostated plate to avoid evaporation. The 240 µm diameter gold-plated glass fiberoptic pin (Fiberguide Industries) has a hydrophobic side surface and a hydrophilic upper surface, keeping the application solution at the tip of the pin. A solution containing oligonucleotide is applied to the pin by pipette below the slide,

5 1 which will be mounted in a manually operated microchip holder beneath a binocular
2 microscope lens. The pin table is rotated under the selected gel pad and the solution
3 transferred by downward movement of the slide, bringing the surface of the pad into
10 4 brief contact with the head of the pin. The microchip holder is then shifted to the
5 position of the next pad, and the operation repeated after washing and applying
6 another oligonucleotide solution to the pin head.

15 8 The first of these custom microchips has been designed for the mu opioid receptor for
9 validation of this technology with DNA samples that have already been sequenced by
10 traditional methods [57]. Six oligonucleotides are immobilized on a microchip for
20 11 validation of the three known SNPs in the MOR receptor in exon 1. Position 17: gel-
12 GCGACGGGGGTG-5' (SEQ ID No:1); gel-GCGACAGGGGTG-5' (SEQ ID No:2).
13 Position 24: gel-GGGTGCTTGCGG-5' (SEQ ID No:3); gel-GGGTGTTTGCGG-5'
14 (SEQ ID No:4). Position 118: gel-CTACCGTTGGAC-5' (SEQ ID No:5); gel-
25 15 CTACCGCTGGAC-5' (SEQ ID No:6). In some cases, empirical methods are used to
16 optimize the positioning of these mismatches with respect to the end of the
17 oligonucleotide. This analysis is applied to the two known SNPs in the third exon of
18 the MOR. Preparation is carried out of a new chip with gel pads containing the
30 19 oligonucleotides described above as well as four additional gel pads containing
20 oligonucleotides corresponding to the known SNPs in exon 3. Position 779: gel-
21 GAACGCGGAGTT-5' (SEQ ID No:7); gel-GAACGTGGAGTT (SEQ ID No:8).
35 22 Position 942: gel-TGATGCAAGGTC-5' (SEQ ID No:9); gel-TGATGTAAGGTC
23 (SEQ ID No:10). Various control oligonucleotides are included on gel pads on this
24 chip. Target DNA prepared using two separate sets of primers corresponding to
25 approximately positions 1, 140 and 760, 955 are fractionated, labeled and hybridized
40 26 together on this second microchip. (Nucleotide numbering is defined as beginning
27 with the first A of the initiation codon).

28
29 This type of chip will be available for increasing throughput of analysis of MOR
45 30 SNPs from patients.
31

5
1 Genetic microarray chips for sequencing selected exon regions. Genetic microchips
2 containing arrays of all 4096 hexamer oligonucleotides, and 24 control DNA
3 sequences, are utilized for sequencing selected exon regions of genes from the
10 4 subjects in this proposed study [174]. For validation of this technology, work begins
5 with analysis of DNA from subjects previously characterized for SNPs in the mu
6 opioid receptor gene (Bond et al., 1998). Selected exon regions are analyzed from the
7 KOR and ORL1 receptor, including the amino terminus, the first, second and third
15 8 extracellular loops, the third intracellular loop, and the carboxyl terminus, regions
9 which have been shown to be important for receptor function. Regions selected for
10 sequencing are approximately 150 bases in length.

20 11
12 Fluorescent-labeled target DNA (~100 pmol) is hybridized to the custom microchip in
13 appropriate solutions of formamide with 0.9 M NaCl, 1 mM EDTA, 1% Tween 20,
14 and 50 mM sodium phosphate buffer (pH 7.0) at optimized temperatures for from 6-
25 15 18 hr. Selected regions of genomic DNA is amplified by PCR, fragmented by acidic
16 depurination, and end-labelled with fluorescent chromophores. This target material is
17 hybridized to genetic microchips containing arrays of gel pads. The pattern of
18 hybridization is analyzed by proprietary software developed at the Argonne National
30 19 Laboratories [147,174]. Genetic microarray chips for sequencing selected exon
20 regions. Genetic microchips containing arrays of the 4096 hexamer oligonucleotides,
21 and 24 control DNA sequences, are utilized for sequencing selected exon regions of
35 22 genes from the subjects.

23
24 Following identification of polymorphisms and defining the genotypes of the study
25 subjects, genetic analyses is performed. Two types of data are collected in this study:
40 26 case-control data and sib-pair data. Each type of data is analyzed separately. For the
27 case-control data, the eight candidate genes outlined above are studied. Novel
28 polymorphic alleles identified using the methods described above are analyzed for
29 association and linkage.
45 30

31 Sample Sizes. Cases with opiate addiction and controls with no history of opioid or
32 other dependence are ascertained. The controls and cases are matched by ethnic

background. The example provided in Table 1 concerns the total number of cases and controls necessary to detect an association with power of 0.8 ($b=0.2$) and $a=0.01$. Sample size calculations were carried out for equal numbers of cases and controls [175]. In section A of Table 1, allele frequencies were used for the sample size calculations. It should be noted that for this situation each case and control make up two observations, since each individual has two alleles at every locus. In section B of Table 1 sample size calculations using genotype frequencies are shown. Individuals which are heterozygous and homozygous for the polymorphism of interest are grouped together. For these sample size calculations the proportion of each genotype was calculated based upon the assumption that they are in Hardy-Weinberg equilibrium.

Table 1

Total Frequency of Polymorphism	Percent Increase in Allele frequency between cases and controls	Section A		Total Sample Size (cases and controls)	Section B			Total Sample Size (Cases and Controls)
		Frequency Polymorphism group A*	Frequency Polymorphism group B*		frequency of individuals homozygous and heterozygous for the polymorphism	frequency of individuals homozygous and heterozygous for the polymorphism in group A*	frequency of individuals homozygous and heterozygous for the polymorphism in group B*	
0.05	300.0	0.01	0.04	1,130	0.0975	0.0195	0.078	1,110
0.05	400.0	0.008333	0.041667	922	0.0975	0.01625	0.08125	904
0.05	500.0	0.007143	0.042857	806	0.0975	0.0139285	0.0835714	790
0.1	200.0	0.025	0.075	770	0.19	0.0475	0.1425	740
0.1	300.0	0.02	0.08	540	0.19	0.038	0.152	518
0.15	200.0	0.0375	0.1125	488	0.2775	0.069375	0.208125	460
0.15	300.0	0.03	0.12	342	0.2775	0.0555	0.222	322
0.2	100.0	0.066667	0.133333	770	0.36	0.12	0.24	706
0.2	200.0	0.05	0.15	348	0.36	0.09	0.27	450

*Either Group A or Group B can be cases or controls.

As an example, in one study of the mu opioid receptor [57], allele frequencies of 0.11 and 0.07, for A118G and C17T SNPs, respectively, were observed. For the C17T polymorphism there was a 6.6 fold increase in the polymorphism for cases. With 900 cases and controls available for study, Table 1 demonstrates that the sample sizes are sufficient to detect an association in a variety of conditions.

5
1 Data Analysis. Exact tests for Hardy-Weinberg Equilibrium ([176], implemented in
2 MLD program available at <http://statgen.ncsu.edu/#software>) are carried out on cases
3 and controls stratified by ethnic groups as well as for the non-stratified case and
10 4 control groups. The data is stratified by ethnic group and opiate dependency status for
5 each of the polymorphism studied. The pooled relative risk (RR) and the Mantel-
6 Haenszel chi-square [177] are calculated. Chi-square tests of homogeneity is also
7 carried out to test for differences in RR between ethnic groups. These analyses are
15 8 carried out using both allele and genotype frequency data.

9
10 As noted hereinabove, the definition of polymorphisms of genes the expression of
20 11 which is known to be altered during or exposure to drugs of abuse or addiction is of
12 profound importance in enhancing the understanding of the neurobiology of addictive
13 disease and the roots of individual variation in the vulnerability to develop addictions.
14 In addition, knowledge of the polymorphisms will enhance our understanding of
25 15 normal physiology and other disease states, and will provide the pharmacogenomic
16 basis for the development of targeted therapeutics. As noted above, the foregoing
17 description extends to the neurotransmitter gene families described above and top the
30 18 conditions and diseases which arise from or are related or linked to alterations in gene
19 expression and/or polymorphisms, including single-nucleotide polymorphisms,
20 additions, deletions, and other mutations. These various embodiments are fully
21 embraced herein.

35 22
23 Particular neurotransmitters receptors were prepared and analyzed in accordance with
24 the invention, and the figures attached hereto are demonstrative of the procedures and
25 results.

40 26
27 Various publications are cited herein including those below, the disclosures of which
28 are incorporated by reference in their entireties.

45 29
30 [1] National Household Survey on Drug Abuse: Population Estimates 1996.
31 Substance Abuse and Mental Health Services Administration, Office of Applied
32 Studies. US Department of Health and Human Services, Rockland, MD July 1997.

- [2] Harwood H, Fountain D, Livermore G (1998): The economic costs of alcohol and drug abuse in the United States 1992. NIH (NIDA) Pub Num 98-4327.
- [3] Mogil JS, Sternberg WF, Marek P, Sadowski B, Belknap JK, Liebeskind JC (1996): The genetics of pain and pain inhibition. *Proc Natl Acad Sci USA* 93: 3048-3055.
- [4] Pasternak GW (1993): Pharmacological mechanisms of opioid analgesics. *Clin Neuropharmacol* 16: 1-18.
- [5] Grove WM, Eckert ED, Heston L, Bouchard TJJ, Segal N, Lykken DT (1990): Heritability of substance abuse and antisocial behavior: a study of monozygotic twins reared apart. *Biol Psychiatry* 27: 1293-1304.
- [6] Kendler KS, Prescott CA, Neale MC, Pedersen NL (1997): Temperance board registration for alcohol abuse in a national sample of Swedish male twins, born 1902 to 1949. *Arch Gen Psychiatry* 54: 178-184.
- [7] Pedersen NL, Floderus-Myrhed B (1984): Twin analysis as a potential tool for examining psychosocial factors associated with and preceding smoking behaviors. *Acta Geneticae Medicae Gemellologiae* 33: 413-424.
- [8] Rounsaville BJ, Kosten TR, Weissman MM, Prusoff B, Pauls D, Anton SF, Merikangas K (1991) Psychiatric disorders in relatives of probands with opiate addiction. *Arch Gen Psychiatry* 48: 33-42.
- [9] Tsuang MT, Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, Meyer JM, Toomey R, Faraone SV, Eaves L (1996): Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. *Am J Med Genet* 67: 473-477.
- [10] Tsuang MT, Lyons MJ, Meyer JM, Doyle T, Eisen SA, Goldberg J, True W, Lin N, Toomey R, Eaves L (1998): Co-occurrence of abuse of different drugs in men. *Arch Gen Psychiatry* 55: 967-972.
- [11] Bierut LJ, Dinwiddie SH, Begleiter H, Crowe RR, Hesselbrock V, Numberger JJ, Porjesz B, Schuckit MA, Reich T (1998): Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking. *Arch Gen Psychiatry* 55: 982-988.
- [12] Merikangas KR, Stolar M, Stevens DE, Goulet J, Preisig MA, Fenton B, Zhang H, O'Malley SS, Rounsaville BJ (1998): Familial transmission of substance use disorders. *Arch Gen Psychiatry* 55: 973-979.

- [13] Sudakov SK, Goldberg SR., Borisova EV, Surkova LA, Turina IV, Rusakov DJu, Elmer GI (1993): Differences in morphine reinforcement property in two inbred rat strains: associations with cortical receptors, behavioral activity, analgesia and the cataleptic effects of morphine. *Psychopharmacol* 112: 183-188.
- [14] Schlussman SD, Ho A, Zhou Y, Curtis AE, Kreek MJ (1998): Effects of "binge" pattern cocaine on stereotypy and locomotor activity in C57BL/6J and 129/J mice. *Pharmacol Biochem Behav* 60: 593-599.
- [15] Elmer GI, Mathura CB, Goldberg SR (1993): Genetic factors in conditioned tolerance to the analgesic effects of etonitazene. *Pharmacol Biochem Behav* 45: 251-253.
- [16] Elmer GI, Pieper JO, Goldberg SR, George FR (1995): Opioid operant self-administration, analgesia, stimulation and respiratory depression in mu-deficient mice. *Psychopharmacology* 117: 23-31.
- [17] Elmer GI, Pieper JO, Negus SS, Woods JH (1998): Genetic variance in nociception and its relationship to the potency of morphine-induced analgesia in thermal and chemical tests. *Pain* 75: 129-140.
- [18] Mansson E, Bare L, Yang D (1994): Isolation of a human κ -opioid receptor cDNA from placenta. *Biochem Biophys Res Commun* 202: 1431-1437.
- [19] Simonin F, Gaveriaux-Ruff C, Befort K, Matthes H, Lannes B, Micheletti G, Mattei M-G, Charron G, Bloch B, Kieffer, B (1995): κ -Opioid receptor in humans: cDNA and genomic cloning; chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. *Proc Natl Acad Sci USA* 92: 7006-7010.
- [20] Horikawa S, Takai T, Toyosato M, Takahashi H, Noda M, Kakidani H, Kubo T, Hirose T, Inayama S, Hayashida H, Miyata T, Numa S (1983): Isolation and structural organization of the human preproenkephalin B gene. *Nature* 306: 611-614.
- [21] Mollereau C, Parmentier M, Mailleux P, Butour J-L, Moisand C, Chalon P, Caput D, Vassart G, Meunier J-C (1994): ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. *FEBS Lett* 341: 33-38.

- 5
1 [22] Mollereau C, Simons M-J, Soularue P, Liners F, Vassart G, Meunier, J-C,
2 Parmentier M (1996): Structure, tissue distribution, and chromosomal localization of
3 the prepronociceptin gene. *Proc Natl Acad Sci USA* 93: 8666-8670.
- 10 4 [23] Noda M, Teranishi Y, Takahashi H, Toyosato M, Notake M, Nakanishi S,
5 Numa S (1982): Isolation and structural organization of the human preproenkephalin
6 gene. *Nature* 297: 431-434.
- 15 7 [24] Comb M, Seeburg PH, Adelman J, Eiden L, Herbert E (1982): Primary
8 structure of the human Met- and Leu-enkephalin precursor and its mRNA. *Nature*,
9 295: 663-666.
- 20 10 [25] Shibahara S, Morimoto Y, Furutani Y, Notake M, Takahashi H, Shimizu S,
11 Horikawa S, Numa S (1983): Isolation and sequence analysis of the human
12 corticotropin-releasing factor precursor gene. *EMBO j.*, 2: 775-779.
- 25 13 [26] Chen R, Lewis KA, Perrin MH, Vale WW (1993): Expression cloning of a
14 human corticotropin-releasing-factor receptor. *Proc Natl Acad Sci USA* 90: 8967-
15 8971.
- 30 16 [27] Vita N, Laurent P, Lefort S, Chalon P, Lelias JM, Kaghad M, Le Fur G,
17 Caput D, Ferrara P (1993): Primary structure and functional expression of mouse
18 pituitary and human brain corticotrophin releasing factor receptors. *FEBS Lett* 335:
19 1-5.
- 35 20 [28] Chang AC, Cochet M, Cohen SN (1980): Structural organization of human
21 genomic DNA encoding the pro-opiomelanocortin peptide. *Proc Natl Acad Sci USA*
22 77: 4890-4894.
- 40 23 [29] Whitfeld PL, Seeburg PH, Shine J (1982): The human pro-opiomelanocortin
24 gene: organization, sequence, and interspersed with repetitive DNA. *DNA* 1: 133-
25 143.
- 45 26 [30] Takahashi H, Teranishi Y, Nakanishi S, Numa S (1981): Isolation and
27 structural organization of the human corticotropin--lipotropin precursor gene. *FEBS*
28 *Lett* 135: 97-102, 1981.
- 50 29 [31] Yuferov V, Zhou Y, Spangler R, Maggos CE, Ho A, Kreek MJ (1999):
30 Acute "binge" cocaine increases mu opioid receptor mRNA levels in areas of the rat
31 mesolimbic mesocortical dopamine system. *Brain Res Bulletin* in press.

- [32] Unterwald EM, Horne-King J, Kreek MJ (1992): Chronic cocaine alters brain mu opioid receptors. *Brain Res* 584: 314-318.
- [33] Hand TH, Koob GF, Stinus L, LeMoat M (1988): Aversive properties of opiate receptor blockade are centrally mediated and are potentiated by previous exposure to opiates. *Brain Res* 474: 364-368.
- [34] Kreek MJ, Hartman N (1982): Chronic use of opioids and antipsychotic drugs: side effects, effects on endogenous opioids and toxicity. *Ann NY Acad Sci* 398: 151-172.
- [35] Kosten TR, Kreek MJ, Raghunath J, Kleber HD (1986): Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. *Biological Psychiatry* 21: 217- 220.
- [36] Kosten TR, Kreek MJ, Raghunath J, Kleber HD (1986): A preliminary study of beta-endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. *Life Sciences* 39: 55-59.
- [37] Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP (1992): Naltrexone in the treatment of alcohol dependence. *Arch Gen Psychiatry* 49: 876-880.
- [38] Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP (1995): Effect of naltrexone on alcohol "high" in alcoholics. *Amer J of Psych* 152: 613-15.
- [39] O'Malley SS, Jaffe AJ, Change G, Schottenfeld RS, Meyer RE, Rounsaville BJ (1992): Naltrexone and coping skills therapy for alcohol dependence. *Arch Gen Psychiatry* 49: 881-887.
- [40] Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E (1994): A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. *Alcohol Clin Exp Res* 18: 1162-1167.
- [41] King AC, Volpicelli JR, Gunduz M, O'Brien CO, Kreek MJ (1997): Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. *Alcoholism Clin and Exp Res* 21(5): 906-909.
- [42] Kreek MJ (1981): Metabolic interactions between opiates and alcohol. *Ann NY Acad Sci* 362: 36-49.

- 5
1 [43] Adams JU, Holtzman SG (1990): Pharmacologic characterization of the
2 sensitization to the rate-decreasing effects of naltrexone induced by acute opioid
3 pretreatment in rats. *J Pharmacol Exp Ther* 253: 483-489.
- 10
4 [44] Bickel WK, Stitzer ML, Liebson IA, Bicklow OE (1988): Acute physical
5 dependence in man: effects of naloxone after brief morphine exposure. *J Pharmacol*
6 *Exp Ther* 244: 126-132.
- 15
7 [45] Culpepper-Morgan JA, Kreek MJ (1997): HPA axis hypersensitivity to
8 naloxone in opioid dependence: a case of naloxone induced withdrawal. *Metabolism*
9 46: 130-134.
- 20
10 [46] Culpepper-Morgan JA, Inturrisi CE, Portenoy RK, Foley K, Houde RW,
11 Marsh F, Kreek MJ (1992): Treatment of opioid induced constipation with oral
12 naloxone: a pilot study. *Clin Pharm Ther* 23: 90-95.
- 25
13 [47] Heishman SJ, Stitzer NIL, Bigelow GE, Liebson IA (1939): Acute opioid
14 physical dependence in humans: effect of varying the morphine-naloxone interval. *J*
15 *Pharmacol Exp Ther* 250: 485-491.
- 30
16 [48] Heishman SJ, Stitzer NIL, Bigelow GE, Liebson IA (1989): Acute opioid
17 physical dependence in post-addict humans: naloxone dose effects after brief
18 morphine exposure. *J Pharmacol Exp Ther* 248: 127-134.
- 35
19 [49] Jones RT (1979): Dependence in non-addict humans after a single dose of
20 morphine. In: Way EL ed *Endogenous and Exogenous Opioid Agonists and*
21 *Antagonists*. Pergamon Press, New York.
- 40
22 [50] Rosen MI, McMahon TJ, Margolin A, Gill TS, Woods SW, Pearsall HR,
23 Kreek MJ, Kosten TR (1995): Reliability of sequential naloxone challenge tests.
24 *Amer J Drug Alc Abuse* 4: 453-467.
- 45
25 [51] Rosen MI, McMahon TJ, Hameedi FA, Pearsall HR, Woods SW, Kreek MJ,
26 Kosten TR (1996): Effect of clonidine pretreatment on naloxone-precipitated opiate
27 withdrawal. *J Pharmacol Exp Ther* 276: 1128-1135.
- 50
28 [52] Berrettini WH, Ferraro TN, Alexander AC, Buchberg AM, Vogel WH
29 (1994): Quantitative trait loci mapping of three loci controlling morphine preference
30 using inbred mouse strains. *Nature Genet* 7: 54-58.

- [53] Alexander RC, Heydt D, Ferraro TN, Vogel W, Berrettini WH (1996): Further evidence for a quantitative trait locus on murine chromosome 10 controlling morphine preference in inbred mice. *Psychiatr Genet* 6: 29-31.
- [54] Kozak CA, Fillie J, Adamson MC, Chen Y, Yu L (1994): Murine chromosomal location of the mu and kappa opioid receptor genes. *Genomics* 21: 659-661.
- [55] Bergen AW, Kokoszka J, Peterson R, Long JC, Virkkunen M, Linnoila M, Goldman D (1997): Mu opioid receptor gene variants: lack of association with alcohol dependence. *Mol Psychiatry* 2: 490-494.
- [56] Berrettini WH, Hoehe MR, Ferrada TN, Gotthel E (1997): Human mu opioid receptor gene polymorphisms and vulnerability to substance abuse. *Addiction Biol* 2: 303-308.
- [57] Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L (1998): Variation in receptor function from a single nucleotide polymorphism in the human mu opioid receptor gene: possible implications for opioid addiction. *Proc Nat Acad Sci (USA)* 95: 9608-9613.
- [58] Spangler R, Ho A, Zhou Y, Maggos C, Yuferov V, Kreek MJ (1996): Regulation of kappa opioid receptor mRNA in the rat brain by "binge" pattern cocaine administration and correlation with preprodynorphin mRNA. *Mol Brain Res* 38: 71-76.
- [59] Spangler R, Zhou Y, Maggos CE, Schlussman S, Ho A, Kreek MJ (1997): Persistent preprodynorphin and kappa opioid receptor mRNA responses to cocaine occur acutely. Abstracts of the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence, Nashville, TN, June.
- [60] Spangler R, Zhou Y, Maggos CE, Schlussman SD, Ho A, Kreek MJ (1997): Prodynorphin, proenkephalin and kappa opioid receptor mRNA responses to acute "binge" cocaine. *Mol Brain Res* 44: 139-142.
- [61] Unterwald EM, Kreek MJ (1993): Kappa and delta opioid receptor densities following chronic repeated cocaine administration. In: Abstracts of the International Narcotics Research Conference.

- [62] Hurd YL, Brown EE, Finlay JM, Fibiger HC, Gerfen, CR (1992): Cocaine self-administration differentially alters mRNA expression of striatal peptides. *Mol Brain Res* 13: 165-170.
- [63] Daunais JB, Roberts DC, McGinty JF (1993): Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. *NeuroReport* 4: 543-546.
- [64] Kreek MJ, Schluger J, Borg L, Gunduz M, Ho, A (1999): Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions. *J Pharmacol Exp Ther* 288: 260-269.
- [65] Yasuda K, Espinos III R, Takeda J, Le Beau MM, Bell GI (1994): Localization of the kappa opioid receptor gene to human chromosome band 8q11.2. *Genomics* 19: 596-597.
- [66] Litt M, Buroker NE, Kondoleon S, Douglass J, Liston D, Sheehy R, Magenis RE (1988): Chromosomal localization of the human proenkephalin and prodynorphin genes. *Am J Hum Genet* 42: 327-334.
- [67] Geijer T, Jönsson E, Neiman J, Gyllander A, Sedvall F, Rydberg, U, Terenius L (1997): Prodynorphin allelic distribution in Scandinavian chronic alcoholics. *Alcohol Clin Exper Res* 21: 1333-1336.
- [68] Lightman SL, Young WS, III (1987): Changes in hypothalamic preproenkephalin A mRNA following stress and opiate withdrawal. *Nature* 328: 643-645.
- [69] Uhl GR, Ryan JP, Schwartz JP (1988): Morphine alters preproenkephalin gene expression. *Brain Res* 459: 391-397.
- [70] Cohen BM, Van Nguyen T, Hyman SE (1990): Cocaine induced changes in the rat brain. *NIDA Res Monograph* 105: 175-181.
- [71] Borsook D, Falkowski O, Rosen H, Comb M, Hyman SE (1994): Opioids modulate stress-induced proenkephalin gene expression in the hypothalamus of transgenic mice: a model of endogenous opioid gene regulation by exogenous opioids. *J Neurosci* 14: 7261-7271.
- [72] LaForge KS, Yuferov V, Zhou Y, Ho A, Kreek MJ (1998): "Binge" cocaine administration alters preproenkephalin mRNA levels in the guinea pig brain. In

- 5 1 Harris LS ed Problems of Drug Dependence, 1997; Proceedings of the 59th Annual
2 2 Scientific Meeting of the College on Problems of Drug Dependence. National
3 3 Institute of Drug Abuse Research Monograph Series Washington, DC Supt of Docs
10 4 US Govt Print Off DHHS Pub No (ADM)98-4305 178: 83.
5 5 [73] Hurd YL, Herkenham M (1993): Molecular alterations in the neostriatum
6 6 of human cocaine addicts. *Synapse* 13: 357-369.
7 7 [74] Chan RJ, McBride AW, Thomasson HR, Ykenney A, Crabb DW (1994):
15 8 Allele frequencies of the preproenkephalin A (PENK) gene CA repeat in Asians,
9 9 African-Americans, and Caucasians: lack of evidence for different allele frequencies
10 10 in alcoholics. *Alcohol Clin Exp Res* 18: 533-535.
20 11 [75] Mikesell MJ, Sobell JL, Sommer SS, McMurray CT (1996): Identification
12 12 of a missense mutation and several polymorphisms in the proenkephalin A gene of
13 13 schizophrenic patients. *Am J Med Genet* 67: 459-467.
14 14 [76] Mikesell MJ, Barron YD, Nimgaonkar VL, Sobell JL, Sommer SS,
25 15 McMurray CT (1997): Gly(247)àAsp proenkephalin A mutation is rare in
16 16 schizophrenia populations. *Am J Med Genet* 74: 213-215.
17 17 [77] Darland T, Heinricher MM, Grandy DK (1998): Orphanin FQ/nociceptin: a
18 18 role in pain and analgesia, but so much more. *Trends in Neurosci* 21(5): 215-221.
30 19 [78] Meunier J-C, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P,
20 20 Butour J-L, Guillemot J-C, Ferrara P, Monsarrat B, Mazargull H, Vassart G,
21 21 Parmentier M, Costentin J (1995): Isolation and structure of the endogenous agonist
22 22 of opioid receptor-like ORL1 receptor. *Nature* 377: 532-535.
35 23 [79] Lightman SL, Young WS, III (1988): Corticotropin-releasing factor,
24 24 vasopressin and pro-opiomelanocortin mRNA responses to stress and opiates in the
25 25 rat. *J Physiol* 403: 511-523.
40 26 [80] Mocchetti I, Ritter A, Costa E (1989): Down-regulation of
27 27 proopi melanocortin synthesis and beta-endorphin utilization in hypothalamus of
28 28 morphine-tolerant rats. *J Mol Neurosci* 1: 33-38.
29 29 [81] Bronstein DM, Przewlocki R, Akil H (1990): Effects of morphine treatment
45 30 on pro-opiomelanocortin systems in rat brain. *Brain Res* 519: 102-111.
31 31 [82] Gudeithlu de Yebenes E, Tejawani GA, Bhargava HN (1991): Beta-
32 32 endorphin and methionine-enkephalin levels in discrete brain regions, spinal cord,

1 pituitary gland and plasma of morphine tolerant-dependent and abstinent rats. Brain
2 Res 553: 284-290.

3 [83] Wardlaw SL, Kim J & Sobieszczyk S 1996 Effect of morphine on
4 proopiomelanocortin gene expression and peptide levels in the hypothalamus. Mol
5 Brain Res 41: 140-147.

6 [84] Kreek MJ (1973): Medical safety and side effects of methadone in tolerant
7 individuals. J Amer Med Assn 223: 665-668.

8 [85] Kreek MJ (1978): Medical complications in methadone patients. Ann NY
9 Acad Sci 311: 110-134.

10 [86] Kreek MJ, Wardlaw SL, Friedman J, Schneider B, Frantz AG (1981):
11 Effects of chronic exogenous opioid administration on levels of one endogenous
12 opioid (beta-endorphin) in man. Advances in Endogenous and Exogenous Opioids,
13 Simon E, Takagi H eds Tokyo, Japan: Kodansha Ltd. Publishers, 364--366.

14 [87] Kreek MJ, Raghunath J, Plevy S, Hamer D, Schneider B, Hartman N
15 (1984): ACTH, cortisol and beta-endorphin response to metyrapone testing during
16 chronic methadone maintenance treatment in humans. Neuropeptides, 5: 277-278.

17 [88] Kreek MJ (1992): Rationale for maintenance pharmacotherapy of opiate
18 dependence. In: CP O'Brien, JH Jaffe eds Addictive States. Raven Press, Ltd.:New
19 York, 205-230.

20 [89] Kreek MJ (1996): Opiates, opioids and addiction. Mol Psych 1: 232-254.

21 [90] Kreek MJ (1996): Opioid receptors: Some perspectives from early studies
22 of their role in normal physiology, stress responsivity and in specific addictive
23 diseases. Journal of Neurochemical Res 21: 1469-1488.

24 [91] Rivier C, Vale W (1987): Cocaine stimulates adrenocorticotropin (ACTH)
25 secretion through a corticotropin-releasing factor (CRF)-mediated mechanism. Brain
26 Res 422: 403-406.

27 [92] Rivier C, Lee S (1994): Stimulatory effect of cocaine on ACTH secretion:
28 Role of the hypothalamus. Mol Cell Neurosci 5: 189-195.

29 [93] Zhou Y, Spangler R, LaForge KS, Maggos CE, Ho A, Kreek MJ (1996):
30 Corticotropin-releasing factor and CRF-R1 mRNAs in rat brain and pituitary during
31 "binge" pattern cocaine administration and chronic withdrawal. J Pharmacol Exp
32 Ther 279: 351-358.

- [94] Samyai Z, Biro E, Gardi J, Vecsernyes M, Julesz J, Telegdy G (1995): Brain corticotropin-releasing factor mediates 'anxiety-like' behavior induced by cocaine withdrawal in rats. *Brain Res* 675: 89-97
- [95] DeVries AC, Pert, A (1998): Conditioned increases in anxiogenic-like behavior following exposure to contextual stimuli associated with cocaine are mediated by corticotropin-releasing factor. *Psychopharmacology* 137(4): 333-40.
- [96] Ambrosio E, Sharpe LG, Pilote NS (1997): Regional binding to corticotropin releasing factor receptors in brain of rats exposed to chronic cocaine and cocaine withdrawal. *Synapse* 25(3): 272-6.
- [97] Zhou Y, Spangler R, LaForge KS, Maggos CE, Kreek, MJ (1996): Modulation of CRF-mRNA in rat anterior pituitary by dexamethasone: correlation with POMC mRNA. *Peptides* 17: 435-441.
- [98] Richter RM, Pich EM, Koob GF, Weiss F (1995): Sensitization of cocaine-stimulated increase in extracellular levels of corticotropin-releasing factor from the rat amygdala after repeated administration as determined by intracranial microdialysis. *Neuroscience Letters* 187(3): 169-72.
- [99] Samyai Z, Biro E, Penke B, Telegdy G (1992): The cocaine-induced elevation of plasma corticosterone is mediated by endogenous corticotropin-releasing factor (CRF) in rats. *Brain Res* 589(1): 154-6.
- [100] Goeders NE, Bienvenu OJ, De Souza EB (1990): Chronic cocaine administration alters corticotropin-releasing factor receptors in the rat brain. *Brain Res* 531(1-2): 322-8.
- [101] Schluger JH, Perret G, McClary K, Gunduz M, Disla I, Myers JE, Daniels J, Ho A, Kreek, MJ (1998): Differential stimulation of the HPA axis by CRF in normal volunteers and in patients with addictions. In: Harris LS ed *Problems of Drug Dependence 1998; Proceedings of the 60th Annual Scientific Meeting for the College on problems of Drug Dependence*. National Institute of Drug Abuse Research Monograph Series, Washington DC Supt of Docs US Govt Print Off, in press.
- [102] Knych ET, Prohaska JR (1981): Effect of chronic intoxication and naloxone on the ethanol-induced increase in plasma corticosterone, *Life Sci* 28: 1987-1994
- [103] Guaza C, Torrellas A, Borrell S (1983): Adrenocortical response to acute and chronic ethanol administration in rats, *Psychopharmacology* 79: 173-176.

- 5
1 [104] Rivier C, Vale W (1988): Interaction between ethanol and stress on ACTH
2 and beta-endorphin secretion, *Alcohol Clin Exp Res*, 12: 206-210.
- 3 [105] Rivier C, Imaki T, Vale W (1990): Prolonged exposure to alcohol: effect on
10 4 CRF mRNA levels, and CRF- and stress-induced ACTH secretion in the rat, *Brain*
5 *Res* 520: 1-5.
- 6 [106] Arbiser JL, Morton CC, Bruns GAP, Majzoub JA (1988): Human
7 corticotropin releasing hormone gene is located on the long arm of chromosome 8.
15 8 *Cell Genet* 47: 113-116.
- 9 [107] Vamvakopoulos NC, Chrousos GP (1993): Regulated activity of the distal
10 promoter-like element of the human corticotropin-releasing hormone gene and
11 secondary structural features of its corresponding transcripts. *Mol Cell Endocrinol*
20 12 94: 73-78.
- 13 [108] Baerwald CG, Panayai GS, Lanchbury JS (1997): A new XmnI
14 polymorphism in the regulatory region of the corticotropin releasing hormone gene.
25 15 *Hum Genet* 97: 697-698.
- 16 [109] Baerwald CG, Panayai GS, Lanchbury JS (1997): Corticotropin releasing
17 hormone promoter region polymorphisms in rheumatoid arthritis. *J Rheumatol* 24:
18 215-216.
- 30 19 [110] Gu J, Sadler L, Daiger S, Wells D, Wagner M (1993): Dinucleotide repeat
20 polymorphism at the CRH gene. *Hum Mol Genet* 2: 85.
- 21 [111] Stratakis CA, Sarlis NJ, Berrettini WH, Badner JA, Chrousos GP, Gershon
22 ES, Detera-Wadleigh SD (1997): Lack of linkage between the corticotropin-releasing
35 23 hormone (CRH) gene and bipolar affective disorder. *Mol Psychiatry* 2: 483-485.
- 24 [112] Kyllö JH, Collins MM, Vetter KL, Cuttler L, Rosenfield RL, Donohoue PA
25 (1996): Linkage of congenital isolated adrenocorticotrophic hormone deficiency to the
40 26 corticotropin releasing hormone locus using simple sequence repeat polymorphisms.
27 *Am J Med Genet* 62: 262-267.
- 28 [113] Vamvakopoulos NC, Sioutopoulou TO (1994): Human corticotropin-
29 releasing hormone receptor gene (CRHR) is located on the long arm of chromosome
45 30 17 (17q12-qter). *Chromosome Res* 2: 471-473.

- [114] Polymeropoulos MH, Torres R, Yanovski JA, Chandrasekharappa SC, Ledbetter DH (1995): The human corticotropin-releasing factor receptor (CRHR) gene maps to chromosome 17q12-q22. *Genomics* 28:123-124.
- [115] Hughes J, Smith TW, Kosterlitz HW, Fothergill LA, Morgan MA, Morris HR (1975): Identification of two related pentapeptides from the brain with potent opiate agonist activity. *Nature* 258: 577-580.
- [116] Przewlocki R, Holtt V, Duka TH, Kleber G, Gramsch CH, Haarmann I, Herz A (1979): Long-term morphine treatment decreases endorphin levels in rat brain and pituitary. *Brain Res* 174: 357-361.
- [117] Ragavan VV, Wardlaw SL, Kreek MJ, Frantz AG (1983): Effects of chronic naltrexone and methadone administration on brain immunoreactivity beta-endorphin in the rat. *Neuroendocrinology* 37: 266-268.
- [118] Schluger J, Bodner G, Gunduz M, Ho A, Kreek, MJ (1998): Abnormal metyrapone tests during cocaine abstinence. In: Harris LS ed Problems of Drug Dependence 1997; Proceedings of the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Washington, DC:Supt of Docs, US Govt Print Off DHHS Pub No (ADM)98-4305,178: 105.
- [119] Aouizerate B, Schluger JH, Perret G, McClary K, Ho A, Piazza PV, Kreek, MJ (1999): Enhanced sensitivity to negative glucocorticoid feedback in methadone patients with ongoing cocaine dependence. In: Harris LS (ed.), Problems of Drug Dependence, 1998; Proceedings of the 60th Annual Scientific Meeting of the College on problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series, Washington, DC:Supt Of Docs, US Govt Print Off, in press.
- [120] Seizinger BR, Bovermann K, Holtt V, Herz A (1984): Enhanced activity of the endorphinergic system in the anterior and neurointermediate lobe of the rat pituitary gland after chronic treatment with ethanol liquid diet. *J Pharmacol Exp Ther* 230: 455-461.
- [121] Gianoulakis C, Hutchison WD, Kalant H (1988): Effects of ethanol treatment and withdrawal on biosynthesis and processing of proopiomelanocortin by the rat neurointermediate lobe. *Endocrinology* 122:817-825.

- [122] Dave JR, Eiden LE, Karanian JW, Eskay RL (1986): Ethanol exposure decreases pituitary corticotropin-releasing factor binding, adenylate cyclase activity, proopiomelanocortin biosynthesis and plasma beta-endorphin levels in the rat. *Endocrinology* 118: 280-286.
- [123] Angelogianni P, Gianoulakis C (1993): Chronic ethanol increases proopiomelanocortin gene expression in the rat hypothalamus. *Neuroendocrinology* 57: 106-114.
- [124] Kreek MJ, Koob GF (1998): Drug dependence: Stress and dysregulation of brain reward pathways. *Drug and Alc Dep* 51: 23-47.
- [125] Owerbach D, Rutter WJ, Roberts JL, Wittfield P, Shine J, Seeburg PH, Shows TB (1981): The proopiomelanocortin (adrenocorticotropin/b-lipoprotein) gene is located on chromosome 2 in humans. *Somatic Cell Genet* 7: 359-369.
- [126] Zabel BU, Naylor SL, Sakaguchi AY, Bell GI, Shows TB (1983): High-resolution chromosomal localization of human genes for amylase, proopiomelanocortin, somatostatin, and a DNA fragment (D3S1) by in situ hybridization. *Proc Natl Acad Sci USA* 80: 6932-6936.
- [127] Feder J, Migone N, Chandg AC, Cochet M, Cohen SN, Cann H, Cavalli-Sforza LL (1983): A DNA polymorphism in close physical linkage with the proopiomelanocortin gene. *Am J Hum Genet* 35: 1090-1096.
- [128] Feder J, Gurling HM, Darby J, Cavalli-Sforza LL (1985): DNA restriction fragment analysis of the proopiomelanocortin gene in schizophrenia and bipolar disorders. *Am J Hum Genet* 37: 286-294.
- [129] Gostout B, Liu Q, Sommer SS (1993): "Cryptic" repeating triplets of purines and pyrimidines (cRRY(i)) are frequent and polymorphic: analysis of coding cRRY (I) in the proopiomelanocortin (POMC) and TATA-binding protein (TPB) genes. *Am J Hum Genet* 52: 1182-1190.
- [130] Morris JC, Bertram CE, Lowry PJ, Savva D (1994): Cryptic trinucleotide repeat polymorphism in the POMC gene. *Hum Mol Genet* 3: 2080.
- [131] Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A (1998): Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. *Nature Genetics* 19: 155-157.

5

10

15

20

25

30

35

40

45

50

55

- [132] Befort K, Mattei MG, Roeckel N, Kieffer, BL (1994): Chromosomal localization of the δ opioid receptor gene to human lp34.3-p36.1 and mouse 4D bands by in situ hybridization. *Genomics* 20: 143-145.
- [133] Mayer P, Rochlitz H, Rauch E, Rommelspacher H, Hasse HE, Schmidt S, Höllt V (1997): Association between a delta opioid receptor gene polymorphism and heroin dependence in man. *NeuroReport* 8: 2547-2550.
- [134] Orita M, Suzuki Y, Sekiya T and Hayashi K (1989): Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. *Genomics* 5: 874-879.
- [135] Hayashi K (1991): PCR-SSCP: a simple and sensitive method for detection of mutations in the genomic DNA. *PCR Methods Appl* 1: 34-38.
- [136] White MB, Carvalho M, Derse D, O'Brian SJ, and Dean M (1993): Detecting single base substitutions as heteroduplex polymorphisms. *Genomics* 12: 3031-306.
- [137] Grompe M (1993): The rapid detection of unknown mutations in nucleic acids. *Nature Genet* 5: 111-117.
- [138] Wu DY, Ugozzoli L, Pal BK, Wallace RB (1989): Allele-specific enzymatic amplification of beta-globin genomic DNA for diagnosis of sickle cell anemia. *Proc Natl Acad Sci USA* 86: 2757-2760.
- [139] Sarkar G, Cassady J, Bottema CDK, and Sommer, SS (1990): Characterization of polymerase chain reaction amplification of specific alleles. *Anal Biochem* 186: 64-68.
- [140] Hayashi K, Yandell DW (1993): How sensitive is PCR-SSCP? *Hum Mutat* 2: 338-346.
- [141] Jordanova A, Kalaydjieva L, Savov A, Claustress M, Schwartz M, Estivill X, Angeligheva D, Haworth A, Casals T, Kremensky I (1997): SSCP analysis: A blind sensitivity trial. *Hum Mutat* 10: 65-70.
- [142] Lander ES (1999): Array of hope. *Nature Genetics* suppl 21: 3-5.
- [143] Southern E, Kalim M, Shchepinov M (1999): Molecular interactions on microarrays. *Nature Genetics* suppl 21: 5-9.
- [144] Cheung VG, Morley M, Aguilar F, Massimi A, Kucherlapti F, Childs G (1999): Making and reading microarrays. *Nature Genetics* suppl 21: 15-19.

5 1 [145] Lipshutz, RJ, Fodor PA, Gingeras TR, Lockhart DJ (1999): High density
2 synthetic oligonucleotide arrays. Nature Genetics suppl 21: 20-24.

3 [146] Hacia JG (1999): Resequencing and mutational analysis using
10 4 oligonucleotide microarrays. Nature
5

6 The present invention is not to be limited in scope by the specific embodiments
7 describe herein. Indeed, various modifications of the invention in addition to those
15 8 described herein will become apparent to those skilled in the art from the foregoing
9 description and the accompanying figures. Such modifications are intended to fall
10 within the scope of the appended claims.

11
20 12 It is further to be understood that all base sizes or amino acid sizes, and all molecular
13 weight or molecular mass values, given for nucleic acids or polypeptides are
14 approximate, and are provided for description.

Claims

5

10

15

20

25

30

35

40

45

50

55

WHAT IS CLAIMED IS:

1. A method for making a biological chip plate comprising the steps of:
 - (a) providing a body comprising a plurality of defining spaces;
 - (b) providing a wafer comprising on its surface a plurality of probe arrays, each probe array comprising a collection of probes, at least two of which are different, arranged in a spatially defined and physically addressable manner; and
 - (c) wherein the probe arrays are selected from a family of neurotransmitter genes known to be affected by exposure to addictive agents and/or alcohol.
2. The method of claim 1 wherein the probes are DNA or RNA molecules.
3. The method of claim 1 wherein said neurotransmitter genes are selected from the group consisting of opioid system genes, dopaminergic system genes, serotonin system genes, signal transducer genes, acetylcholine receptor genes, GABA receptor (muscarinic) genes, glutamate receptor genes, and NMDA receptor genes.
4. The method of claim 3 wherein said opioid system genes are selected from the group consisting the mu opioid receptor, kappa opioid receptor, delta opioid receptor, prodynorphin, the mu opioid receptor, the delta opioid receptor, preproenkephalin, the opioid-like receptor 1, orphanin FQ (prepronociceptin), preproenkephalin, nociceptin, corticotropin releasing factor and the corticotropin releasing factor receptor type I, preproopiomelanocortin, and any combination thereof.
5. The method of claim 3 wherein said dopaminergic system gene is dopaminergic receptor D1-D5 and dopamine transporter.

- 5
10
15
20
25
30
35
40
45
50
55
- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
6. The method of claim 3 wherein said serotonin system gene is melatonin, serotonin receptors (5-HT_{1,2,3,4,5,6,7} and subtypes), serotonin transporter, or a norepinephrin receptor.
7. The method of claim 3 wherein said signal transducer gene is adenylyl cyclase, DARPP-32, dopamine D1 receptor, dopamine D2 receptor, and calcineurin.
8. The method of claim 4 wherein said neurotransmitter genes are associated with a genetic predisposition to, susceptibility to, development of, characteristics of, or persistence of a physiological or pathological response to a neurotransmitter factor-related condition, anomaly, aberration, disorder or dysfunction.
9. The method of claim 8 wherein said neurotransmitter factor-related condition is addiction.
10. The method of claim 9 wherein said addiction is opiate, cocaine or alcohol addiction.
11. The method of claim 8 wherein said neurotransmitter genes are opioid receptor system genes.
12. The method of claim 11 wherein said opioid system genes are selected from the group consisting the mu opioid receptor, kappa opioid receptor, delta opioid receptor, prodynorphin, the mu opioid receptor, the delta opioid receptor, preproenkephalin, the opioid-like receptor 1, orphanin FQ (prepronociceptin), preproenkephalin, nociceptin, corticotropin releasing factor and the corticotropin releasing factor receptor type I, preproopiomelanocortin, and any combination thereof.

5

10

15

20

25

30

35

40

45

50

55

13. A method for identifying a genetic predisposition to, susceptibility to, development of, characteristics of, or persistence of a physiological or pathological response to a neurotransmitter factor-related condition, anomaly, aberration, disorder or dysfunction, comprising identifying, using a multiple biological sample array, genetic polymorphisms in a plurality of neurotransmitter genes associated with said neurotransmitter factor-related condition, anomaly, aberration, disorder or dysfunction.

14. The method of claim 13 wherein said neurotransmitter genes are selected from the group consisting of opioid system genes, dopaminergic system genes, serotonin system genes, signal transducer genes, acetylcholine receptor genes, GABA receptor (muscarinic) genes, glutamate receptor genes, and NMDA receptor genes.

15. The method of claim 14 wherein said dopaminergic system gene is dopaminergic receptor D1-D5 and dopamine transporter.

16. The method of claim 14 wherein said serotonin system gene is melatonin, serotonin receptors (5-HT₁, 2, 3, 4, 5, 6, 7 and subtypes), serotonin transporter, or a norepinephrin receptor.

17. The method of claim 14 wherein said signal transducer gene is adenylyl cyclase, DARPP-32, dopamine D1 receptor, dopamine D2 receptor, and calcineurin.

18. The method of claim 14 wherein said neurotransmitter genes are opioid system receptor genes.

20. The method of claim 13 wherein said genes are selected from the group consisting of the mu opioid receptor, kappa opioid receptor, delta opioid receptor, preprodynorphin, the mu opioid receptor, the delta opioid receptor, preproenkephalin, the opioid-like receptor 1, orphanin FQ

- 5
1 (prepronociceptin), preproenkephalin, nociceptin, corticotropin releasing
2 factor and the corticotropin releasing factor receptor type I,
3 preproopiomelanocortin, and any combination thereof.
- 10
4
5 21. The method of claim 13 wherein said genetic polymorphisms are associated
6 with a neurotransmitter factor-related condition, anomaly, aberration,
7 disorder or dysfunction.
- 15
8
9 22. The method of claim 13 wherein said polymorphisms are not associated
10 with a neurotransmitter factor-related condition, anomaly, aberration,
11 disorder or dysfunction.
- 20
12
13 23. The method of claim 13 wherein said polymorphisms are identified in DNA
14 or in RNA.
- 25
15
16 24. The method of claim 13 wherein said neurotransmitter factor-related
17 condition is selected from the group consisting of neurologic disorder or
18 dysfunction, response to pain, stress, gastrointestinal function, immune
19 function, reproductive function, and signal transduction.
- 30
20
21 25. The method of claim 13 wherein said neurotransmitter factor-related
22 condition is associated with a neurological disorder or dysfunction.
- 35
23
24 26. The method of claim 25 wherein said neurologic disorder is selected from
25 the group consisting of addiction, schizophrenia, Tourette syndrome, drug
26 abuse, attention deficit disorder, anxiety, depression, obsessive-compulsive
27 disorder, stroke, obesity, response to pain, hypertension, vascular disorders,
28 migraine, nausea, Alzheimer disease, aggressive behavior, premenstrual
29 syndrome, diabetic neuropathy, suppression of alcohol intake, and
30 Parkinson disease.
- 45
31

5

1 27. The method of claim 26 wherein said addiction is opiate addiction, cocaine
2 addiction, or alcohol addiction.
3

10

4 28. The method of claim 27 wherein said opiate addiction is heroin addiction.
5

15

6 29. A method for identifying a genetic predisposition to, susceptibility to,
7 development of, characteristics of, or persistence of a physiological or
8 pathological response to a neurotransmitter factor-related condition,
9 anomaly, aberration, disorder or dysfunction, comprising identifying, using
10 a biological sample array, gene expression in a plurality of opioid system
11 genes associated with said neurotransmitter factor-related condition,
12 anomaly, aberration, disorder or dysfunction.
13

20

14 30. The method of claim 29 wherein said neurotransmitter genes are selected
15 from the group consisting of opioid system genes, dopaminergic system
16 genes, serotonin system genes, signal transducer genes, acetylcholine
17 receptor genes, GABA receptor (muscarinic) genes, glutamate receptor
18 genes, and NMDA receptor genes.
19

30

20 31. The method of claim 30 wherein said dopaminergic system gene is
21 dopaminergic receptor D1-D5 and dopamine transporter.
22

35

23 32. The method of claim 30 wherein said serotonin system gene is melatonin,
24 serotonin receptors (5-HT₁, 2, 3, 4, 5, 6, 7 and subtypes), serotonin transporter,
25 or a norepinephrin receptor.
26

40

27 33. The method of claim 30 wherein said signal transducer gene is adenylyl
28 cyclase, DARPP-32, dopamine D1 receptor, dopamine D2 receptor, and
29 calcineurin.
30

45

31 34. The method of claim 30 wherein said acetylcholine receptor (nicotinic) is
32 -E and subtypes.
33

50

55

5

10

15

20

25

30

35

40

45

50

55

- 1 35. The method of claim 29 wherein said neurotransmitter genes are opioid
2 receptor genes.
3
- 4 36. The method of claim 35 wherein said genes are selected from the group
5 consisting of the mu opioid receptor, kappa opioid receptor, delta opioid
6 receptor, prodynorphin, the mu opioid receptor, the delta opioid receptor,
7 preproenkephalin, the opioid-like receptor 1, orphanin FQ
8 (prepronociceptin), preproenkephalin, nociceptin, corticotropin releasing
9 factor and the corticotropin releasing factor receptor type I,
10 preproopiomelanocortin, and any combination thereof.
11
- 12 37. The method of claim 29 wherein said neurotransmitter factor-related
13 condition is selected from the group consisting of neurologic disorder or
14 dysfunction, response to pain, stress, gastrointestinal function, immune
15 function, reproductive function, and signal transduction.
16
- 17 38. The method of claim 37 wherein said neurotransmitter factor-related
18 condition is associated with a neurological disorder or dysfunction.
19
- 20 39. The method of claim 38 wherein said neurologic disorder is selected from
21 the group consisting of addiction, schizophrenia, Tourette syndrome, drug
22 abuse, attention deficit disorder, anxiety, depression, obsessive-compulsive
23 disorder, stroke, obesity, response to pain, hypertension, vascular disorders,
24 migraine, nausea, Alzheimer disease, aggressive behavior, premenstrual
25 syndrome, diabetic neuropathy, suppression of alcohol intake, and
26 Parkinson disease.
27
- 28 40. The method of claim 39 wherein said addiction is opiate addiction, cocaine
29 addiction, or alcohol addiction.
30
- 31 41. The method of claim 40 wherein said opiate addiction is heroin addiction.
32

5

10

15

20

25

30

35

40

45

50

55

- 1 42. A method for making a biological chip plate comprising the steps of:
- 2 (a) providing a body comprising a plurality of wells defining spaces;
- 3 (b) providing a wafer comprising on its surface a plurality of probe
- 4 arrays, each probe array comprising a collection of probes, at least
- 5 two of which are different, arranged in a spatially defined and
- 6 physically addressable manner;
- 7 (c) attaching the wafer to the body so that the probe arrays are exposed
- 8 to the spaces of the wells;
- 9 (d) wherein the probe arrays are selected from a family of
- 10 neurotransmitter genes known to be involved in a neurologic
- 11 disorder or dysfunction, response to pain, stress, gastrointestinal
- 12 function, immune function, reproductive function, or signal
- 13 transduction.
- 14
- 15 43. The method of claim 42 wherein the probes are DNA or RNA molecules.
- 16
- 17 44. A method for making a biological chip plate comprising the steps of
- 18 providing a wafer comprising on its surface a plurality of probe arrays, each
- 19 probe array comprising a collection of probes, at least two of which are
- 20 different, arranged in a spatially defined and physically addressable manner;
- 21 and applying a material resistant to the flow of a liquid sample so as to
- 22 surround the probe arrays, thereby creating test wells.
- 23
- 24 45. The method of claim 44 wherein said probes are DNA or RNA molecules.
- 25
- 26
- 27
- 28

FIG. 1

Preparation of Target RNA for Human Mu Opioid
Receptor SNP Identification by Hybridization to
Custom Gel Pad Microarrays





FIG. 2

Identification of C17T SNP of Human Mu Opioid
Receptor by Hybridization to Custom Gel Pad
Oligonucleotide Microarrays



3/7

FIG. 3

Identification of A118G SNP of Human Mu Opioid
Receptor by Hybridization to Custom
Gel Pad Oligonucleotide Microarrays




FIG. 4

Experimental Design for Human Mu Opioid Receptor SNP Identification Using Custom Gel Pad Microarrays




FIG. 5

Chemical Labeling of Fragment Target RNA with Texas Red Bromoacetamide




FIG. 6

Fluorescence Intensity of Custom Gel Pad Microarray Following Hybridization to Human Mu Opioid Receptor Exon I Target RNA





FIG. 7

Fluorescence Microscope Image of Custom Gel Pad
Microarray Following Hybridization to Human Mu
Opioid Receptor Exon 1 Target RNA



1 SEQUENCES

2

3 GCGACGGGGGTG-5' (SEQ ID No:1)

4

5 GCGACAGGGGTG-5' (SEQ ID No:2)

6

7 GGGTGCTTGCGG-5' (SEQ ID No:3)

8

9 GGGTGTTTGCGG-5' (SEQ ID No:4)

10

11 CTACCGTTGGAC-5' (SEQ ID No:5)

12

13 CTACCGCTGGAC-5' (SEQ ID No:6)

14

15 GAACGCGGAGTT-5' (SEQ ID No:7)

16

17 GAACGTGGAGTT (SEQ ID No:8)

18

19 TGATGCAAGGTC-5' (SEQ ID No:9)

20

21 TGATGTAAGGTC (SEQ ID No:10)

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 00/16706

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C12Q1/68 801J19/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C12Q 801J		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, MEDLINE, BIOSIS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 545 531 A (FODOR STEPHEN P A ET AL) 13 August 1996 (1996-08-13) cited in the application column 1-2; claims	44,45
Y	---	1-43
Y	US 5 550 021 A (BLUM KENNETH ET AL) 27 August 1996 (1996-08-27) the whole document	1-43
Y	FR 2 668 771 A (INST NAT SANTE RECH MED) 7 May 1992 (1992-05-07) page 15-19; claim 11 claim 15	1-43
Y	WO 98 07426 A (GLAXO GROUP LTD ;PEROUTKA STEPHEN J (US)) 26 February 1998 (1998-02-26) the whole document	1-43
-/-		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>*A* document defining the general state of the art which is not considered to be of particular relevance</p> <p>*E* earlier document but published on or after the international filing date</p> <p>*L* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>*O* document referring to an oral disclosure, use, exhibition or other means</p> <p>*P* document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>*Z* document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search <div style="text-align: center;">5 October 2000</div>		Date of mailing of the international search report <div style="text-align: center;">16/10/2000</div>
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer <div style="text-align: center;">Reuter, U</div>

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 00/16706

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DATABASE WPI Section Ch, Week 199422 Derwent Publications Ltd., London, GB; Class B04, AN 1994-178255 XP002149363 abstract & FR 2 697 850 A (UNIV PASTEUR) 13 May 1994 (1994-05-13)	1-43
Y	WO 98 33937 A (MAX DELBRUECK CENTRUM ;HOEHE MARGRET (DE); WENDEL BIRGIT (DE)) 6 August 1998 (1998-08-06) the whole document	1-43
Y	US 5 763 183 A (KOULU MARKKU ET AL) 9 June 1998 (1998-06-09) the whole document	1-43
Y	WO 96 31621 A (COLLIER DAVID ;KERWIN ROBERT (GB); ROBERTS GARETH WYN (GB); SMITHK) 10 October 1996 (1996-10-10) the whole document	1-43
Y	US 5 882 893 A (GOODEARL ANDREW D J) 16 March 1999 (1999-03-16) the whole document	1-43
Y	WO 96 29404 A (SIBIA NEUROSCIENCES INC ;DAGGETT LORRIE P (US); LU CHIN CHUN (US)) 26 September 1996 (1996-09-26) page 11-12; claim 15	1-43
Y	WO 97 46675 A (CIBA GEIGY AG ;KAUPMANN KLEMENS (DE); BETTLER BERNHARD (CH); BITTI) 11 December 1997 (1997-12-11) page 1-2; claim 9	1-43
Y	WO 98 53103 A (BIBILASHVILLI ROBERT ;CHENCHIK ALEX (US); JOKHADZE GEORGE (US); CL) 26 November 1998 (1998-11-26) page 1-14; table 1	1-12, 42, 43
A	WO 98 14427 A (HOECHST MARION ROUSSEL INC) 9 April 1998 (1998-04-09) page 1 page 69-71	1-43
P,X	GB 2 339 200 A (GENOSTIC PHARMA LTD) 19 January 2000 (2000-01-19) abstract; claims 1,8,11 page 16 page 67-71	1-45

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/16706

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5545531 A	13-08-1996	US 5874219 A	23-02-1999
US 5550021 A	27-08-1996	US 5500343 A	19-03-1996
		US 5210016 A	11-05-1993
		AT 139803 T	15-07-1996
		CA 2074519 A	08-08-1991
		DE 69120526 D	01-08-1996
		DE 69120526 T	13-02-1997
		DK 514490 T	04-11-1996
		EP 0514490 A	25-11-1992
		WO 9112339 A	22-08-1991
FR 2668771 A	07-05-1992	AT 180788 T	15-06-1999
		AU 8857991 A	26-05-1992
		CA 2072874 A	07-05-1992
		DE 69131289 D	08-07-1999
		DE 69131289 T	16-12-1999
		EP 0507908 A	14-10-1992
		ES 2134781 T	16-10-1999
		WO 9207937 A	14-05-1992
		JP 5503219 T	03-06-1993
WO 9807426 A	26-02-1998	AU 4083797 A	06-03-1998
		EP 1014977 A	05-07-2000